Literatur zu Buchteil II
Literatur zu Kap. 10
1.
2.
3.
4.
5.
Agarwal, S.K., Gelsema, A.J., Calaresu, F.R. (1990) Inhibition of rostral
VLM by baroreceptor activation is relayed through caudal VLM. Am J
Physiol 258, R1271–R1278
Andresen, M.C., Kunze, D.L. (1994) Nucleus tractus solitarius – gateway
to neural circulatory control. Annu Rev Physiol 56, 93–116
Bader, M., Peters, J., Baltatu, O., Muller, D.N., Luft, F.C., Ganten, D.
(2001) Tissue renin-angiotensin systems: new insights from experimental
animal models in hypertension research. J Mol Med 79, 76–102
Busse R. (2000) Gefäßsystem und Kreislaufregulation. In Physiologie des
Menschen (Schmidt, R.F., Thews, G., Lang, F., eds.), Springer, Berlin
Heidelberg, pp 498–561
Busse, R., Fleming, I. (1995) Regulation and functional consequences of
endothelial nitric oxide formation. Ann Med 27, 331–340
6.
7.
8.
9.
10.
11.
Chalmers, J., Arnolda, L., Llewellyn-Smith, I., Minson, J., Pilowsky, P.
(1994) Central nervous control of blood pressure. In Textbook of
Hypertension (Swales, J.D., ed.), Blackwell Scientific Publications,
London, pp 409–426
Chen, H.H., Burnett, J.C. (2000) Natriuretic peptides in the
pathophysiology of congestive heart failure. Curr Cardiol Rep 2, 198–205
Christensen, N.J., Galbo, H. (1983) Sympathetic nervous activity during
exercise. Annu Rev Physiol 45139–45153
Cowley, A.W.Jr. (1992) Long-term control of arterial blood pressure.
Physiol Rev 72, 231–300
Cowley, A.W.Jr. (1997) Role of the renal medulla in volume and arterial
pressure regulation. Am J Physiol 273, R1-R15
Dampney, R.A.L., Tagawa, T., Horiuchi, J., Potts, P.D., Fontes, M.,
Polson, J.W. (2001) What drives the tonic acitivity of presynaptic neurons
12.
13.
14.
15.
16.
in the rostral ventrolateral medulla? Clin Exp Pharmacol Physiol 27,
1049–1053
Davis, M.J., Hill, M.A. (1999) Signaling mechanisms underlying the
vascular myogenic response. Physiol Rev 79, 387–423
de Wardener, H.E. (2001) The hypothalamus and hypertension. Physiol
Rev 81, 1599–1658
Delp, M.D., Laughlin, M.H. (1998) Regulation of skeletal muscle
perfusion during exercise. Acta Physiol Scand 162, 411–419
Eich, R.H., Cuddy, R.P., Smulyan, H., Lyons, R.H. (1966) Hemodynamics
in labile hypertension: a follow-up study. Circulation 34, 299–307
Esler, M., Jennings, G., Korner, P., Willett, I., Dudley, F., Hasking, G.,
Anderson, W., Lambert, G. (1988) Assessment of human sympathetic
nervous system activity from measurements of norepinephrine turnover.
Hypertension 11, 3–20
17.
18.
19.
20.
21.
22.
Fleming, I., Busse, R. (1999) NO: the primary EDRF. J Mol Cell Cardiol
31, 5–14
Folkow, B. (1982) Physiological aspects of primary hypertension. Physiol
Rev 62, 347–504
Frohlich, E.D., Apstein, C., Chobanian, A.V., Devereux, R.B., Dustan,
H.P., Dzau, V., Fauad-Tarazi, F., Horan, M.J., Marcus, M., Massie, B.
(1992) The heart in hypertension. N Engl J Med 327, 998–1008
Funder, J.W., Pearce, P.T., Smith, R., Smith, A.I. (1988)
Mineralocorticoid action: target tissue specificity is enzyme, not receptor,
mediated. Science 242, 583–585
Gewirtz, H. (1991) The coronary circulation: limitations of current
concepts of metabolic control. News Physiol Sci 6, 265–268
Goldsmith, S.R. (1987) Vasopressin as vasopressor. Am J Med 82, 1213–
1219
23.
24.
25.
26.
27.
Goldstein, D.S., Golczynska, A., Stuhlmuller, J., Holmes, C., Rea, R.F.,
Grossman, E., Lenders, J. (1999) A test of the "epinephrine hypothesis" in
humans. Hypertension 33, 36–43
Grassi, G., Mancia, G. (1994) Arterial baroreflexes and other
cardiovascular reflexes in hypertension. In: Textbook of Hypertension
(Swales, J.D., ed.), Blackwell Scientific Publications, London, pp 397–408
Grisk, O., Klöting, I., Exner, J., Spiess, S., Schmidt, R., Junghans, D.,
Lorenz, G., Rettig, R. (2002) Long-term arterial pressure in spontaneously
hypertensive rats is set by the kidney. J Hypertens 20, 1–8
Grisk, O., Rettig, R. (2001) Renal transplantation studies in genetic
hypertension. News Physiol Sci 16, 262–264
Guidi, E., Menghetti, D., Milani, S., Montagnino, G., Palazzi, P., Bianchi,
G. (1996) Hypertension may be transplanted with the kidney in humans: a
long-term historical prospective follow-up of recipients grafted with
28.
29.
30.
31.
kidneys coming from donors with or without hypertension in their
families. J Am Soc Nephrol 7, 1131–1138
Guyton AC (1991) Blood pressure control – special role of the kidneys
and body fluids. Science 252, 1813–1816
Hall, J.E., Granger, J.P. (1994) Role of sodium and fluid excretion in
hypertension. In Textbook of Hypertension (Swales, J.D., ed.), Blackwell
Scientific Publications, London, pp 360–387
Halperin, M.L., Kamel, K.S. (2000) Dynamic interactions between
integrative physiology and molecular medicine: the key to understand the
mechanism of action of aldosterone in the kidney. Can J Physiol
Pharmacol 78, 587–594
Hill, M.A., Zou, H., Potocnik, S.J., Meininger, G.A., Davis, M.J. (2001)
Invited review: arteriolar smooth muscle mechanotransduction: Ca(2+)
signaling pathways underlying myogenic reactivity. J Appl Physiol 91,
973–983
32.
33.
34.
35.
36.
Holtz, J. (1996) Peripheral Circulation: Fundamental concepts,
comparative aspects of control in specific vascular sections, and lymph
flow. In: Comprehensive Human Physiology (Greger, R., Windhorst, U.,
eds.), Springer, Berlin Heidelberg New York, pp 1865–1915
Holzer, P., Wachter, C., Heinemann, A., Jocic, M., Lippe, I.T., Herbert,
M.K. (1995) Sensory nerves, nitric oxide and NANC vasodilatation. Arch
Int Pharmacodyn Ther 329, 67–79
Jänig, W., Häbler, H.J. (2000) Specificity in the organization of the
autonomic nervous system: a basis for precise neural regulation of
homeostatic and protective body functions. Prog Brain Res 122351–
122356
Kirchheim, H.R. (1976) Systemic arterial baroreceptor reflexes. Physiol
Rev 56, 100–176
Kone, B.C. (2001) Molecular biology of natriuretic peptides and nitric
oxide synthases. Cardiovasc Res 51, 429–441
37.
38.
39.
40.
41.
Landahl, S., Bengtsson, C., Sigurdsson, J.A., Svanborg, A., Svardsudd, K.
(1986) Age-related changes in blood pressure. Hypertension 8, 1044–1053
Lund-Johansen, P. (1989) Central haemodynamics in essential
hypertension at rest and during exercise: a 20-year follow-up study. J
Hypertens 7, S52–S55
Lund-Johansen, P. (1994) Haemodynamics of essential hypertension. In
Textbook of Hypertension (Swales, J.D., ed.), Blackwell Scientific
Publications, London, pp 61–76
Majewski, H., Tung, L.H., Rand, M.J. (1981) Hypertension through
adrenaline activation of prejunctional beta-adrenoceptors. Clin Exp
Pharmacol Physiol 8, 463–468
Ming, Z., Han, C., Lautt, W.W. (1999) Nitric oxide mediates hepatic
arterial vascular escape from norepinephrine-induced constriction. Am J
Physiol 277, G1200-G1206
42.
43.
44.
45.
46.
Ngarmukos, Ch., Grekin, R.J. (2001) Nontraditional aspects of aldosterone
physiology. Am J Physiol Endocrinol Metab 281, 1122–1127
Nielsen, S., Chou, C.-L., Marples, D., Christensen, E.I., Kishore, B.K.,
Knepper, M.A. (1995) Vasopressin increases water permeability of kidney
collecting duct by inducing translocation of aquaporin-CD water channels
to plasma membrane. Proc Natl Acad Sci 92, 1013–1017
Palmer, R.M.J., Ferrige, F.G., Moncada, S. (1987) Nitric oxide release
accounts for the biological acitvity of endothelium-derived relaxing factor.
Nature 327, 524–526
Persson, P., Ehmke, H., Kirchheim, H., Seller, H. (1988) Effect of sinoaortic denervation in comparison to cardiopulmonary deafferentiation on
long-term blood pressure in conscious dogs. Pflügers Arch 411, 160–166
Persson, P.B. (1996) Modulation of cardiovascular control mechanisms
and their interaction. Physiol Rev 76, 193–244
47.
48.
49.
50.
51.
Rohrwasser, A., Morgan, T., Dillon, H.F., Zhao, L., Callaway, C.W.,
Hillas, E., Zhang, S., Cheng, T., Inagami, T., Ward, K., Terreros, D.A.,
Lalouel, J.-M. (1999) Elements of a paracrine tubular renin-angiotensin
system along the entire nephron. Hypertension 34, 1265–1274
Roman, R.J. (1990) Alterations in renal medullary hemodynamics and the
pressure-natriuretic response in genetic hypertension. Am J Hypertens 3,
893–900
Rothe, C.F. (1993) Mean circulatory pressure: its meaning and
measurement. J Appl Physiol 74, 499–509
Rowell, L.B. (1974) Human cardiovascular adjustments to exercise and
thermal stress. Physiol Rev 54, 75–159
Scott, J.A., McCormack, D.G. (1999) Nonadrenergic noncholinergic
vasodilation of guinea pig pulmonary arteries is mediated by nitric oxide.
Can J Physiol Pharmacol 77, 89–95
52.
53.
54.
55.
56.
57.
Share, L. (1988) Role of vasopressin in cardiovascular regulation. Physiol
Rev 68, 1248–1284
Shepherd, J.T., Mancia, G. (1986) Reflex control of human cardiovascular
system. Rev Physiol Biochem Pharmacol 105, 3–100
Spyer, K.M. (1994) Central nervous mechanisms contributing to
cardiovascular control. J Physiol 474, 1–19
Stjernquist, M. (1998) Endothelins – vasoactive peptides and growth
factors. Cell Tissue Res 292, 1–9
Stock, P., Liefeldt, L., Paul, M., Ganten, D. (1995) Local reninangiotensin systems in cardiovascular tissues: localization and functional
role. Cardiology 86 Suppl, 12–18
Stoll, M., Steckelings, U.M., Paul, M., Bottari, S.P., Metzger, R., Unger,
T. (1995) The angiotensin AT2-receptor mediates inhibition of cell
proliferation in coronary endothelial cells. J Clin Invest 95, 651–657
58.
59.
60.
61.
62.
Stroth, U., Unger, T. (1999) The renin-angiotensin system and its
receptors. J Cardiovasc Pharmacol 33 Suppl, S21–S28
Sun, M.K., Reis, D.J. (1994) Central neural mechanisms mediating
excitation of sympathetic neurons by hypoxia. Progr Neurobiol 44, 197–
219
Sved, A.F., Schreihofer, A.M., Kost, C.K.Jr. (1997) Blood pressure
regulation in baroreceptor-denervated rats. Clin Exp Pharmacol Physiol
24, 77–82
ter Keurs, H.E.D.J., Tyberg, J.V. (1996) Control of the Circulation: an
integrated view. In Comprehensive Human Physiology (Greger, R.,
Windhorst, U., eds.), Springer, Berlin Heidelberg, pp 1995–2014
Tyberg, J.V. (2002) Venous modulation of ventricular preload. Am Heart J
123, 1098–1104
63.
64.
65.
66.
67.
Unger, T., Chung, O., Csikos, T., Culman, J., Gallinat, S., Gohlke, P.,
Höhle, S., Meffert, S., Stoll, M., Stroth, U., Zhu, Y.Z. (1996) Angiotensin
receptors. J Hypertens Suppl 14, S95–S103
Urata, H., Nishimura, H., Ganten, D. (1996) Chymase-dependent
angiotensin II forming systems in humans. Am J Hypertens 9, 277–284
Wehling, M., Spes, C.H., Win, N., Janson, C.P., Schmidt, B.M., Theisen,
K., Christ, M. (1998) Rapid cardiovascular action of aldosterone in man. J
Clin Endocrinol Metab 83, 3517–3522
Weiss, Y.A., Safar, M.E., London, G.M., Simon, A.C., Levenson, J.A.,
Milliez, P.M. (1978) Repeat hemodynamic determinations in borderline
hypertension. Am J Med 64, 382–387
Westerhaus, M.J., Loewy, A.D. (2001) Central representation of the
sympathetic nervous system in the cerebral cortex. Brain Res 903, 117–
127
Literatur zu Kap. 11
1.
2.
3.
Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid
FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St
Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA,
Stanton LW, Scott J (1999) Identification of Cd36 (Fat) as an insulinresistance gene causing defective fatty acid and glucose metabolism in
hypertensive rats. Nat Genet 21: 76–83
Bader M, Peters J, Baltatu O, Muller DN, Luft FC, Ganten D (2001)
Tissue renin-angiotensin systems: new insights from experimental animal
models in hypertension research. J Mol Med 79: 76–102
Barlassina C, Schork NJ, Manunta P, Citterio L, Sciarrone M, Lanella G,
Bianchi G, Cusi D (2000) Synergistic effect of alpha-adducin and ACE
genes causes blood pressure changes with body sodium and volume
expansion. Kid Int 57: 1083–1090
4.
5.
6.
7.
8.
Bohnemeier H, Paul M (2001) Transgene Animal Model of the Rat for the
Conditional Expression in Kidney and Heart. Dtsch Med Wochenschr 126:
S162(Abstract)
Corvol P, Persu A, A.P., Jeunemaitre X (1999) Seven lessons from two
candidate genes in human essential hypertension: angiotensinogen and
epithelial sodium channel. Hypertension 33: 1324–1331
Feinleib M, Garrison RJ, Fabsitz R, Christian JC, Hrubec Z, Borhani NO,
Kannel WB, Rosenman R, Schwartz JT, Wagner JO (1977) The NHLBI
twin study of cardiovascular disease risk factors: methodology and
summary of results. Am J Epidemiol 106: 284–285
Ferrari P, Bianchi G (2000) Genetic mapping and tailored antihypertensive
therapy. Cardiovasc Drugs Ther 14: 387–395
Harrap SB (1994) Genetic Approaches to Hypertension. In: Swales JD
(Hrsg)Textbook of Hypertension. Blackwell Scientific Publications,
Oxford, S 504–518
9.
10.
11.
12.
Hunt SC, Cook NR, Oberman A, Cutler JA, Hennekens CH, Allender PS,
Walker WG, Whelton PK, Williams RR (1998) Angiotensinogen
genotype, sodium reduction, weight loss, and prevention of hypertension:
trials of hypertension prevention, phase II. Hypertension 32: 393–401
Hunt SC, Hasstedt SJ, Kuida H, Stults BM, Hopkins PN, Williams RR
(1989) Genetic heritability and common environmental components of
resting and stressed blood pressures, lipids, and body mass index in Utah
pedigrees and twins. Am J Epidemiol 129: 625–638
Hunt SC, Williams RR (1994) Genetic Factors in Human Hypertension.
In: Swales JD (Hrsg) Textbook of Hypertension. Blackwell Scientific
Publications, Oxford, S 519–538
Hübner N, Kreutz R (1998) Molekular definierte Modelle in der HerzKreislauf-Forschung. In: Ganten D, Ruckpaul K (Hrsg) Handbuch der
molekularen Medizin. Springer-Verlag, Heidelberg, S 401–412
13.
14.
15.
16.
Hübner N, Lee YA, Lindpaintner K, Ganten D, Kreutz R (1999) Congenic
substitution mapping excludes Sa as a candidate gene locus for a blood
pressure quantitative trait locus on rat chromosome 1. Hypertension 34:
643–648
Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS,
Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM (1992)
Molecular basis of human hypertension: role of angiotensinogen. Cell 71:
169–180
Jordan J, Toka HR, Heusser K, Toka O, Shannon JR, Tank J, Diedrich A,
Stabroth C, Stoffels M, Naraghi R, Oelkers W, Schuster H, Schobel HP,
Haller H, Luft FC (2000) Severely impaired baroreflex-buffering in
patients with monogenic hypertension and neurovascular contact.
Circulation 102: 2611–2618
Kreutz R (2000) Pharmakogenomik und Pharmakogenetik bei der
arteriellen Hypertonie. Dtsch.med.Wochenschr. 125: 1403–1411
17.
18.
19.
20.
Kreutz R und Hübner N (2002) Congenic rat strains are important tools for
the genetic dissection of essential hypertension. Sem Neph 22: 135–147
Kreutz R, Hübner N, James MR, Bihoreau MT, Gaugier D, Lathrop GM,
Ganten D, Lindpaintner K (1995a) Dissection of a quantitative trait locus
for genetic hypertension on rat chromosome 10. Proc.Natl.Acad.Sci.USA
92: 8778–8782
Kreutz R, Hübner N, Ganten D, Lindpaintner K (1995b) Genetic linkage
of the ACE gene to plasma ACE acitivity, but not to blood pressure: a
quantitative trait locus confers identical complex phenotypes in human and
rat hypertension. Circulation 92: 2381–2384
Kreutz R, Kovacevic L, Schulz A, Rothermund L, Ketteler M, Paul M
(2000) Effect of high NaCl diet on spontaneous hypertension in a genetic
rat model with reduced nephron number. J.Hypertens. 18: 777–782
21.
22.
23.
24.
25.
26.
Kreutz R, Paul M, Ganten D (2000) Hypertonie. In: Gerok W, Huber C,
Meinertz T, et al (Hrsg) Die Innere Medizin. Schattauer, Stuttgart, S 377–
399
Kruglyak L, Nickerson DA (2001) Variation is the spice of life. Nat Genet
27: 234–236
Kunz R, Beige J, Kreutz R, Distler A, Sharma AM (1997) Association
between the M235T allele and essential hypertension in caucasians. A
systematic review and methodological appraisal. Hypertension 30: 1331–
1337
Lander ES, Linton LM, Birren B et al. (2001) Initial sequencing and
analysis of the human genome. Nature 409: 860–921
Lifton RP, Gharavi AG, Geller DS (2001) Molecular mechanisms of
human hypertension. Cell 104: 545–556
Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park JK, Schmitz
C, Lippoldt A, Breu V, Dechend R, Dragun D, Schneider W, Ganten D,
27.
28.
29.
30.
Haller H (1999) Hypertension-induced end-organ damage: A new
transgenic approach to an old problem. Hypertension 33: 212–218
Manunta P, Burnier M, D'Amico M, Buzzi L, Maillard M, Barlassina C,
Lanella G, Cusi D, Bianchi G (1999) Adducin polymorphism affects renal
proximal tubule reabsorption in hypertension. Hypertension 33: 694–697
McIlhany ML, Shaffer JW, Hines EAJ (1975) The heritability of blood
pressure: an investigation of 200 pairs of twins using the cold pressor test.
Johns Hopkins Med J 136: 57–64
Morris BJ (1999) Genes essential hypertension: The first decade of
research. In: Frossard PM, Parvez H, Minami M et al. (Hrsg) Progress in
Hypertension Bd 4. VSP, Utrecht, S 1–44
Mullins JJ, Peters J, Ganten D (1990) Fulminant hypertension in
transgenic rats harbouring the mouse Ren-2 gene. Nature (London) 344:
541–544
31.
32.
33.
34.
35.
36.
Passarge E (2000) Genetische Grundlagen der Inneren Medizin. In: Gerok
W, Huber C, Meinertz T, et al (Hrsg) Die Innere Medizin. Schattauer,
Stuttgart, New York, S 21–54
Platt R (1947) Heredity in Hypertension. Quart J Med 16: 115
Rapp JP (2000) Genetic analysis of inherited hypertension in the rat.
Physiol Rev 80: 135–172
Roses AD (2001) Pharmacogenetics. Hum Mol Genet 10: 2261–2267
Rothermund L, Luckert S, Kossmehl P, Paul M, Kreutz R (2001) Renal
Endothelin ET(A)/ET(B) Receptor Imbalance Differentiates Salt-Sensitive
From Salt-Resistant Spontaneous Hypertension. Hypertension 37: 275–
280
Schuster H, Wienker TE, Bahring S, Bilginturan N, Toka HR, Neitzel H,
Jeschke E, Toka O, Gilbert D, Lowe A, Ott J, Haller H, Luft FC (1996)
Severe autosomal dominant hypertension and brachydactyly in a unique
Turkish kindred maps to human chromosome 12. Nat Genet 13: 98–100
37.
38.
39.
40.
Shiozawa M, Provoost AP, van Dokkum RP, Majewski RR, Jacob HJ
(2000) Evidence of gene-gene interactions in the genetic susceptibility to
renal impairment after unilateral nephrectomy. J Am Soc Nephrol 11:
2068–2078
Siegel A-K, Planert M, Kossmehl P, Schulz A, Overlack M, Rothermund
L, Kreutz R (2001) Identifcation of Gene Loci That Protect Against The
Manifestation of Hypertensive Target Organ Damage in Salt-Sensitive
Spontaneous Hypertension. Dtsch Med Wochenschr 126: S162(Abstract)
Smithies O, Kim HS, Takahashi N, Edgell MH (2000) Importance of
quantitative genetic variations in the etiology of hypertension. Kidney Int
58: 2265–2280
Stoll M, Kwitek-Black AE, Cowley AWJ, Harris EL, Harrap SB, Krieger
JE, Printz MP, Provoost AP, Sassard J, Jacob HJ (2000) New target
regions for human hypertension via comparative genomics Genome Res
10: 473–482
41.
42.
43.
44.
45.
Thurston H (1994) Goldblatt, Coarctation and Page Experimental Models
of Renovascular Hypertension. In: Swales JD (Hrsg) Textbook of
Hypertension. Blackwell Scientific Publications, Oxford, S 477–493
Venter JC, Adams MD, Myers EW et al. (2001) The sequence of the
human genome. Science 291: 1304–1351
Ward R (1990) Familial aggregation and genetic epidemiology of blood
pressure. In: Brenner BM, Laragh JH (eds) Hypertension:
Pathophysiology, Diagnosis, and Management. Raven Press, New York,
pp 81–100
Weitz W (1923) Zur Ätiologie der genuinen oder vaskulären
Hypertension. Z Klin Med 96: 151–183
Wilson FH, Disse-Nicodeme S, Choate KA et al. (2001) Human
hypertension caused by mutations in WNK kinases. Science 293: 1107–
1112
Literatur zu Kap. 12
1.
2.
3.
4.
5.
6.
Allen FM Sherrill JW: The treatment of arterial hypertension. J Metab Res
2: 429, 1922
Dahl LK: Salt and Hypertension. Am J Clin Nutrition 25: 231–44, 1972
Meneely GR, Dahl LK: Electrolytes. In: Hypertension: the effects of
sodium chloride. The evidence from animal and human studies. In
Hypertension and its treatment. Med Clin N Am 1961; 45: 271
Fujita T Henry WL, Bartter FC, Lake CR, Delea CS. Factors influencing
blood pressure in salt-sensitive patients with hypertension. Am J Med 69:
334–344, 1980
Morimoto A, Uzu T, Fujii T et al.: Sodium sensitivity and cardiovascular
events in patients with essential hypertension. Lancet 1997; 350: 1734–
1737
Sharma AM, Schattenfroh S, Kribben A, Distler A. Reliability of salt
sensitivity testing. KlinWochenschr 1989; 67: 632–634
7.
8.
9.
10.
11.
Skrabal F, Kotanko P, Wach P et al.: Further advances in the salt
sensitivity hypothesis in man. Klin Wochenschr (1991); 69 Suppl 25: 36–
40
Skrabal F: Aldosterone and in vivo mineralocorticoid activity in
normotensive and hypertensive man. J R Soc Med 1979; 72: 252–259
Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood
pressure: age and pressure change over time. Hypertension 1991; 18: 67–
71
Skrabal F, Herholz H, Neumayr M et al.: Salt sensitivity in humans is
linked to enhanced sympathetic responsiveness and to enhanced proximal
tubular reabsorption. Hypertension 1984; 2: 152–158
Agarwal AK, Giacchetti G, Lavery G et al.: CA-repeat polymorphism in
intron 1 of HSD11B2: effects on gene expression and salt sensitivity.
Hypertension 2000; 36: 187–94
12.
13.
14.
15.
16.
17.
Lovati E, Ferrari P, Dick P et al.: Molecular basis of human salt
sensitivity: the role of the 11 beta-hydroxysteroid dehydrogenase type 2. J
Clin Endocr Metab 1999; 84: 3745–49
Kotanko P, Höglinger O, Skrabal F. β-2 adrenoceptor density in fibroblast
culture correlates with human salt sensitivity. Amer J Physiol 1992; 263:
C623-C627
Gratze G, Fortin J, Labugger R et al.: β-2 adrenergic receptor variants
affect resting blood pressure and agonist-induced vasodilation in
normotensive Caucasians. Hypertension 1999; 33: 1425–1430
Kotanko P, Binder A, Tasker J et al.: Hypertension 1997; 30: 773–776
Draaijer P, Kool MJF, van Bortel LMAB et al.: Vascular compliance in
sodium-sensitive and sodium-resistant borderline hypertensive patients.
Kidney Int 1995; 47: 169–176
Skrabal F, Kotanko P, Lueger A et al.: Augmented reciprocal α2 and β2adrenoceptor changes and rise of total peripheral resistance during increase
18.
19.
20.
21.
22.
of salt intake in salt sensitive man. In "Electrolytes, Volume Homeostasis
and Hypertension", Editors: Luft FC, Ganten D, Springer, Heidelberg New
York 1988, p128– p138
Guyton AC (1991) Blood pressure control – special role of the kidneys
and body fluids. Science 252, 1813–1816
Pettinger WA. Renal α2-adrenergic receptors and hypertension.
Hypertension (1987); 9: 3–6
Wilson Th W, Grim CE. Biohistory of slavery and blood pressure
differences in blacks today. A hypothesis. Hypertension 1991; 17 (Suppl):
I-1222–I-128
Bertaux P: Afrika. In: Fischer Weltgeschichte, Band 32: 73–156, Fischer
Taschenbuchverlag, Frankfurt am Main 1966
Neumayer M, Herholz H, Kotanko P, Skrabal F. Gegensinniger
Kochsalzeinfluss auf die Hämodynamik bei salzsensitiven und
23.
24.
25.
salzresistenten Normotonikern. Nieren- und Hochdruckkrankheiten 1991;
20: 365–370
DASH Salt study. NEJM 2001; 344
Cutler JA, Follmann D, Scott Allender P. Randomized trials of sodium
reduction: an overview. Am J Clin Nutr 1997; 65 (Suppl): 643S–651S
Midgley JP, Matthew AG, Greenwood CMT, Logan AG. Effect of
reduced dietary sodium on blood pressure. A meta-analysis of randomized
controlled trials. JAMA 1996; 275: 1590–1597
Literatur zu Kap. 13
1.
2.
3.
4.
Acheson KJ, Ravussin E, Schoeller DA et al. (1988) Two-week
stimulation for blockade of the sympathetic nervous system in man:
influence of body weight, body composition, and twenty-four hour energy
expenditure. Metabolism 37: 91–98
Alberti KG, Zimmet P (1988) Definition, diagnosis and classification of
diabetes mellitus and its complications. Part 1: diagnosis and classification
of diabetis mellitus. Provisional report of a WHO consultation. Diabet
Med 15: 539–553
Appel LJ, Moore TJ, Obarzanek E et al. (1997) A clinical trial of the
effects of dietary patterns on blood pressure. N Engl J Med 336: 1117–
1124
Bönner G (1994) Hyperinsulinemia, insulin resistance, and hypertension. J
Cardiovasc Pharmacol. 24, Suppl. 2: 39–49
5.
6.
7.
8.
9.
Bonora E, Kiechl S, Willeit J et al. (1998) Prevalence of insulin resistance
in metabolic disorders. Diabetes 47: 1643–1649
Dahlöf B, Devereux RB, Kjeldsen SE et al., for the LIFE study group
(2002) Cardiovascular morbidity and mortality in the losartan intervention
for endpoint reduction in hypertension study (LIFE): a randomised trial
against atenolol. Lancet 359: 995–1003
DeFronzo RA (1981) The effect of insulin on renal sodium metabolism. A
review with clinical implications. Diabetologia 21: 165–171
Després JP, Lamarche B, Mauriége P et al. (1996) Hyperinsulinemia as an
independent risk factor for ischemic heart disease. N Engl J Med 334: 95–
957
Dieterle P, Fehm H, Ströder W et al. (1967) Asymptomatischer Diabetes
mellitus bei normalgewichtigen Hypertonikern. Untersuchungen über die
Glucosetoleranz, das Seruminsulin und die nicht veresterten Fettsäuren bei
der ess. Hypertonie. Dtsch Med Wochenschr 92: 2376–2381
10.
11.
12.
13.
14.
15.
Engeli S, Negrel R, Sharma AM (2000) Physiology and pathophysiology
of the adipose tissue renin-angiotensin system. Hypertension 35: 1270–
1277
Facchini FS, Hollenbeck CB, Jeppesen J et al. (1992) Insulin resistance
and cigarette smoking. Lancet 339: 1128–1130
Feldmann RD, Schmidt ND (2001) Quinalapril treatment enhances
vascular sensitivity to insulin. J Hypertension 19: 113–118
Ferrannini E, Buzzigoli G, Bonadonna R (1987) Insulin resistance in
essential hypertension. N Engl J Med 317: 350–357
Fujii S, Kaku K, Andou S et al. (1993) Glucose and lipid metabolism
during long-term antihypertensive treatment with indapamide in noninsulin dependent diabetic patients. Clin Ther 15: 1041–1050
Gress TW, Nieto FJ, Shahar E et al. (2000) Hypertension and
antihypertensive therapy as risk factors for type 2 diabetes. N Engl J Med
342: 905–912
16.
17.
18.
19.
20.
21.
Haenni A, Lithell H (1999) Moxonidine improves insulin sensitivity in
insulin-resistant hypertensives. J Hypertens 17, Suppl. 3 : S29–S35
Hall JE, Toorn L, Bilo HJG et al. (1990) Chronic hyperinsulinemia and
blood pressure regulation. Am J Physiol 258: F722–F731
Hambrecht R, Wolf A, Gielen S et al. (2000) Effect of exercise on
coronary endothelial function in patients with coronary artery disease. N
Engl J Med 342: 454–460
Hanefeld M, Leonhardt W (1980) Das metabolische Syndrom. Dtsch
Gesund-Wes 36: 545–551
Ikeda T, Gomi T, Hirawa N et al. (1996) Improvement of insulin
sensitivity contributes to blood pressure reduction after weight loss in
hypertensive subjects with obesity. Hypertension 27: 1180–1186
Isomaa B, Lahti K, Almgren P et al. (2001) Cardiovascular morbidity and
mortality associated with the metabolic syndrome. Diabetes Care 24: 683–
689
22.
23.
24.
25.
26.
Jacob S, Balletshofer B, Henriksen EJ et al. (1999) Beta-Blocking agents
in patients with insulin resistance: effects of vasodilating beta-blockers.
Blood Pressure 8: 261–268
Julius S, Valentini M, Palatini P (2000) Overweight and hypertension. A
2-way street? Hypertension 19: 807–813
Kaplan NM (1989) The deadly quartet upper-body obesity, glucose
intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 149:
359–364
Landsberg L, Young JB (1985) The influence of diet on the sympathetic
nervous system. In: Muller EE, MacLeod RM, Frohmann LA et al. (eds)
Neuroendocrine Perspectives. Elsevier, Amsterdam, pp 191–218
Lavrencic A, Salobir BG, Keber I (2000) Physical training improves flowmediated dilation in patients with the polymetabolic syndrome.
Arterioscler Thromb Vasc Biol 20: 55–555
27.
28.
29.
30.
31.
32.
Lissner L, Bengtsson C, Lapidus L et al. (1992) Fasting insulin in relation
to subsequent blood presssure changes and hypertension in women.
Hypertension 20: 797–801
Lithell H (1998) Insulin resistance and diabetes in the context of treatment
of hypertension. Blood Pressure 7, Suppl. 3: 28–31
Modan M, Halkin H, Almog S et al. (1985) Hyperinsulinemia. A Link
between hypertension, obesity and glucose tolerance. J Clin Invest 75:
809–817
Mohamed-Ali, Pinkney JH, Coppack SW (1998) Adipose tissue as an
endocrine and paracrine organ. Int J Obes 22: 1145–1158
Okosun IS, Prewitt TE, Cooper RS (1999) Abdominal obesity in the
United States: prevalence and attributable risk of hypertension. Int Hum
Hypert 13: 425–430
Parrinello G, Scalione R, Pinto A et al. (1996) Central obesity and
hypertension. The role of endothelin. Am J Hypertens 9: 1186–1191
33.
34.
35.
36.
37.
Perticone F, Ceravolo R, Candiogliota M et al. (2000) Obesity and body
fat distribution induce endothelial dysfunction by oxidative stress.
Protective effect of vitamin C. Diabetes 50: 159–165
Petrie JR, Ueda S, Webb DJ et al. (1996) Endothelial nitric oxid
production and insulin sensitivity. A Physiological link with implications
for pathogenesis of cardiovascular disease. Circulation 93: 331–1333
Pollare T, Vesby B, Lithell H (1991) Lipoprothein lipase activity in
sceletal muscle is related to insulin sensitivity. Arterioscler Thromb 11:
1192–1203
Pollare T, Lithell H, Selinus I et al. (1988) Application of prazosin is
associated with an increase of insulin sensitivity in obese patients with
hypertension. Diabetologia 31: 415–420
Pollare T, Lithell H, Berne C (1989) A comparison on the effects of
hydrochlorothiazide and captopril on glucose and lipid metabolism in
patients with hypertension. N Engl J Med 321: 868–873
38.
39.
40.
41.
Pyörälä M, Laakso M, Miettinen H et al. (2001) Plasma insulin and allcause, cardiovascular, and non-cardiovascular mortality. The 22 year
follow-up results of the Helsinki Policemen Study. Diabetes Care 23:
1097–1102
Rabkin SW (1993) Mechanisms of action of adrenergic receptor blockers
on lipids during antihypertensive drug treatment. J Clin Pharmacol 33:
286–291
Reaven GM, Lithell H, Landsberg L (1996) Hypertension and associated
metabolic abnormalities – the role of insulin resistance and the
sympathoadrenal system. N Engl J Med 334: 374–381
Rocchini AP, Key J, Bondie D et al. (1989) The effect of weight loss on
the sensitivity of blood pressure to sodium in obese adolescents. N Engl J
Med 321: 580–585
42.
43.
44.
45.
46.
47.
Ross R, Dagnone D, Jones PJH et al. (2000) Reduction in obesity and
related comorbid conditions after diet-induces weight loss or exerciseinduced weight loss in men. Ann Int Med 133: 133–192
Sasson Z, Rasooly Y, Bhesania T et al. (1993) Insulin resistance is an
important determinant of left ventricular mass in the obese. Circulation 88:
1432–1436
Sharma A, Pischon T, Hardt S et al. (2001) Beta-adrenergic receptor
blockers and weight gain. A systematic analysis. Hypertension 21: 250–
254
Sharma A, Schorr U, Distler A (1993) Insulin resitance in young saltsensitive subjects. Hypertension 21: 167–173
Spitzweg C, Joba W, Heufelder AE (1998) Leptin – neue Erkenntnisse zur
Pathogenese der Adipositas. Med Klinik 93: 478–485
Sprecher DL, Pearce GL (2000) How deadly is the "deadly quartet"? J Am
Coll Caridiol 36: 1159–1165
48.
49.
50.
51.
52.
Vessby B, Uusitupa M, Hermansen et al. (2001) Substituting dietary
saturated for unsaturated fat impairs insulin sensitivity in healthy men and
women. Diabetologia 44: 312–319
Ward KD, Sparrow D, Landsberg L et al. (1996) Influence of insulin,
sympathetic nervous system activity, and obesity on blood pressure: the
Normative Ageing Study. J Hypert 14: 301–308
Wirth A (2000) Adipositas: Epidemiologie, Ätiologie, Folgekrankheiten
und Therapie, 2. überarbeitete u. erweiterte Auflage. Springer, Berlin
Heidelberg New York, 352 S
Wirth A (2001) Metabolisches Syndrom und Herz-Kreislauf-Krankheiten:
klinische Bedeutung und Therapie. In: Rauch B, Held K (Hrsg) Der
schwerkranke und multimorbide Herzpatient. Steinkopf, Darmstadt
Wirth A (2002) Körperliche Aktivität und metabolisches Syndrom. In:
Samitz G, Mensink G (Hrsg) Körperliche Aktivität in Prävention und
Therapie. Marseille Verlag,München, S. 133–144
Literatur zu Kap. 14
Literatur zu Kap. 14.1
1.
Bretza JA, Novey HS et al. (1980) Hypertension: A complication of
danazol therapy. Arch Intern Med 140: 1379–1380
2.
Brummett RE (1984) Warning to otolaryngologists using local
anaesthetics containing epinephrine. Acta Otolaryngol 110: 561
3.
Cain JW (1986) Hypertension associated with oral administration of
physiostigmine in a patient with Alzheimer`s disease. Am J Psychiat 143:
910–912
4.
Clyburn EB, DiPette (1995) Hypertension induced by drugs and other
substances. Seminars in Nephrology 15: 72–86
5.
De Leeuw PW (1997) Drug-Induced Hypertension: Recognition and
Management in Older Patients. Drugs & Ageing 11: 178–185
6.
Diamond JP (1997) Systemic adverse effects of topical ophthalmic agents:
implications for older patients. Drugs Ageing 11: 352–360
7.
8.
9.
10.
11.
Graves SW, Eder JP et al. (1989) Endogenous digoxin-like
immunoreactive factor and digitalis-like factor associated with the
hypertension of patients receiving multiple alcylating agents as part of
autologous bone marrow transplantation. Clin Sci 77: 501–507
Grossman E, Messerli FH (1995) High Blood Pressure. Arch Intern Med
155: 450–460
Khaw KT, Peart WS (1982) Blood pressure and contraceptive use. BMJ
285: 403–407
Kirch W, Strömer K et al. (1989) The influence of prostaglandin inhibition
by indometacin on blood pressure and renal function in hypertensive
patients treated with cilazapril. Br J Clin Pharmacol 27: 297S - 301S
Louie AK, Louie EK et al. (1992) Systemic hypertension associated with
tricyclic antidepressant treatment in patients with panic disorder. Am J
Cardiol 70: 1306–1309
12.
13.
14.
15.
16.
McCauley J, Fung J et al. (1990) The effects of FK 506 on renal function
after liver transplantation. Transplant Proc 22: 17–20
Mene P, Pugliese F, Patrono C (1995) The effects of nonsteroidal antiinflammatory drugs on human hypertensive vascular disease. Seminars in
Nephrology 15: 244–252
Mito RS Yagiela JA (1988) Hypertensive response to levonordefrin in a
patient receiving propranolol: report of a case. J Am Dent Assoc 116: 55–
57
Murburg MM, Villacres EL et al. (1991) Effects of yohimbine on human
sympathetic nervous system function. J Clin Endocrinol Metab 73: 861–
865
Nicholls M et al. (1992) Drug induced hypertension. In: Robertson JLS
(Hrsg) Handbook of Hypertension. Elsevier Science Publishers B.V. S
195–235
17.
18.
19.
20.
21.
22.
23.
Pirpiris M, Sudhir K et al. (1992) Pressor responsiveness in corticosteroidinduced hypertension in humans. Hypertension 19: 567–574
Schmitt JK, Moore JR (1993) Hypertension secondary to chlorpropamide
with amelioration by changing to insulin. Am J Hypertens 6: 317–319
Sheridan C, Chandra P et al. (1982) Transient hypertension after high
doses of metoclopramide. N Engl J Med 307: 1346
Sica DA, Harford AM, Zawada ET (1984) Hypercalcemic hypertension in
hemodialysis. Clin Nephrol 22: 102–104
Smith SR, Ryder C et al. (1984) Cardiovascular and biochemical
responses to nebulised salbutamol in normal subjects. Br J Clin Pharmacol
18: 641–644
Textor SC, Canzanello VJ et al.(1994) Cyclosporine-induced hypertension
after transplantation. Mayo Clin Proc 69(12): 1182–93
Whelan TV (1987) Propranolol, epinephrine and accelerated hypertension
during hemodialysis. Ann Intern Med 106: 327
Literatur zu Kap. 14.2
1.
Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, Semeraro C,
Pocchiari F, Felder RA, Eisner GM, Jose PA. Disruption of the dopamine
D3 receptor gene produces renin-dependent hypertension. J Clin Invest.
1998; 102: 493–498
2.
Badoer E, Wurth H, Turck D, Qadri F, Itoi K, Dominiak P, Unger T. The
K+-induced increases in noradrenaline and dopamine release are
accompanied by reductions in the release of their intraneuronal
metabolites from the rat anterior hypothalamus. An in vivo brain
microdialysis study. Naunyn Schmiedebergs Arch Pharmacol. 1989; 339:
54–59
3.
Bek M, Asico LD, Li XX, et al. AVP-dependent hypertension in mice with
disrupted dopamine D5 receptor [abstract]. J Am Soc Nephrol 1999; 10:
341A
4.
Bek M, Asico LD, Eisner GM, Sibley DR, Jose PA. Non-N-methyl D-
aspartate receptors are involved in the hypertension of D 5 dopamine
5.
6.
7.
8.
9.
receptor knockout mice [abstract]. Hypertension 2000; 36: 726
Bek MJ, Eisner GM, Felder RA, Jose PA. Dopamine receptors in
hypertension. Mt Sinai J Med. 2001; 68: 362–369
Brasch H, Sieroslawski L, Dominiak P. Angiotensin II increases
norepinephrine release from atria by acting on angiotensin subtype 1
receptors. Hypertension. 1993; 22: 699–704
Brodde OE, Michel MC, Gordon EP, Sandoval A, Gilbert EM, Bristow
MR. Beta-adrenoceptor regulation in the human heart: can it be monitored
in circulating lymphocytes? Eur Heart J. 1989; 10 Suppl B: 2–10
Brown MJ, Macquin I. Is adrenaline the cause of essential hypertension?
Lancet. 1981; 2: 1079–1082
Cheng HF, Becker BN, Harris RC. Dopamine decreases expression of
type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest.
1996; 97: 2745–2752
10.
11.
12.
13.
14.
Contreras F, Fouillioux C, Bolivar A, Simonovis N, Hernandez-Hernandez
R, Armas-Hernandez MJ, Velasco M. Dopamine, hypertension and
obesity. J Hum Hypertens. 2002; 16 Suppl 1: S13–77
Dendorfer A, Dominiak P. Characterization of bradykinin receptors
mediating catecholamine release in PC12 cells. Naunyn Schmiedebergs
Arch Pharmacol. 1995; 351: 274–281
Dendorfer A, Hauser W, Falias D, Dominiak P. Bradykinin increases
catecholamine release via B 2 receptors. Pflügers Arch. 1996; 432(3
Suppl): R99–106
Dendorfer A, Thornagel A, Raasch W, Grisk O, Tempel K, Dominiak P.
Angiotensin II induces catecholamine release by direct ganglionic
excitation. Hypertension. 2002; 40: 348–354
DeQuattro V, Campese V, Lurvey A, Yen G, Kypridakis G. Low response
of serum dopamine beta-hydroxylase to stimuli in primary hypertension.
Biochem Med. 1976; 15: 1–9
15.
16.
17.
18.
19.
20.
Dominiak P, Grobecker H. Elevated plasma catecholamines in young
hypertensive and hyperkinetic patients: effect of pindolol. Br J Clin
Pharmacol. 1982; 13(Suppl 2): 381S–390S
Dominiak P. Historic aspects in the identification of the I1 receptor and
the pharmacology of imidazolines. Cardiovasc Drugs Ther. 1994; 8 Suppl
1: 21–26
Dominiak P. Modulation of sympathetic control by ACE inhibitors. Eur
Heart J. 1993; 14 Suppl I: 169–172
Elam M, Grassi G. Adrenaline and hypertension: new evidence for a guilty
verdict? J Hypertens. 2000; 18: 675–677
Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, DelavierKlutchko C, Strosberg AD. Molecular characterization of the human beta
3-adrenergic receptor. Science. 1989; 245: 1118–1121
Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G.
Overflow of catecholamine neurotransmitters to the circulation: source,
21.
22.
23.
24.
25.
fate, and functions. Physiol Rev. 1990; 70: 963–95
Esler M. Clinical application of noradrenaline spillover methodology:
delineation of regional human sympathetic nervous responses. Pharmacol
Toxicol. 1993; 73: 243–253
Feldman RD, Lawton WJ, McArdle WL. Low sodium diet corrects the
defect in lymphocyte beta-adrenergic responsiveness in hypertensive
subjects. J Clin Invest. 1987; 79: 290–294
Feldman RD. Defective venous beta-adrenergic response in borderline
hypertensive subjects is corrected by a low sodium diet. J Clin Invest.
1990; 85: 647–652
Floras JS. Epinephrine and the genesis of hypertension. Hypertension.
1992; 19: 1–18
Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, Kobilka BK.
Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natl
Acad Sci U S A. 1987; 84: 7920–79204
26.
27.
28.
29.
30.
Frtitschka E, Kribben A, Haller H, Hoyer J, Thiede HM, Distler A, Philipp
T. Familial aggregation of altered adrenoceptor density and free
intracellular calcium in patients with essential hypertension. J Cardiovasc
Pharmacol 1987; 10 Suppl 4: S122–S125
Gothert M, Bruss M, Bonisch H, Molderings GJ. Presynaptic imidazoline
receptors. New developments in characterization and classification. Ann
NY Acad Sci. 1999; 881: 171–184
Guzzetti S, Piccaluga E, Casati R, Cerutti S, Lombardi F, Pagani M,
Malliani A. Sympathetic predominance in essential hypertension: a study
employing spectral analysis of heart rate variability. J Hypertens. 1988; 6:
711–717
Hagbarth KE, Vallbo AB. Pulse and respiratory grouping of sympathetic
impulses in human muscle-nerves. Acta Physiol Scand. 1968; 74: 96–108
Holtback U, Kruse MS, Brismar H, Aperia A. Intrarenal dopamine
coordinates the effect of antinatriuretic and natriuretic factors. Acta
31.
32.
33.
34.
35.
36.
Physiol Scand. 2000; 168: 215–218
Huckle WR, Earp HS. Regulation of cell proliferation and growth by
angiotensin II. Prog Growth Factor Res. 1994; 5: 177–194
Iimura O. The role of renal dopaminergic activity in the pathophysiology
of essential hypertension. Jpn Heart J. 1996; 37: 815–828
Jose PA, Eisner GM, Felder RA. Renal dopamine receptors in health and
hypertension. Pharmacol Ther. 1998; 80: 149–182
Kuchel O, Buu NT, Hamet P, Larochelle P, Bourque M, Genest J.
Catecholamine sulfates and platelet phenolsulfotransferase activity in
essential hypertension. J Lab Clin Med. 1984; 104: 238–244
Kuchel O, Shigetomi S. Defective dopamine generation from
dihydroxyphenylalanine in stable essential hypertensive patients.
Hypertension. 1992; 19: 634-63-8
Kuchel O. Peripheral dopamine in hypertension and associated conditions.
J Hum Hypertens. 1999; 13: 605–15
37.
38.
39.
40.
41.
Kuchel O. Genetic determinants of dopaminergic activity: potential role in
blood pressure regulation. Hypertens Res. 1995; 18 Suppl 1: S1–10
Li XX, Asico LD, Low M et al. Disruption of the dopamine D 2 receptor
produces non-renal dependent hypertension [abstract]. J Am Soc Nephrol
1998; 9: 311A
Linthorst AC, van Giersbergen PL, Gras M, Versteeg DH, de Jong W. The
nigrostriatal dopamine system: role in the development of hypertension in
spontaneously hypertensive rats. Brain Res. 1994; 639: 261–268
Lomasney JW, Cotecchia S, Lefkowitz RJ, Caron MG. Molecular biology
of alpha-adrenergic receptors: implications for receptor classification and
for structure-function relationships. Biochim Biophys Acta. 1991; 1095:
127–139
Luippold G, Schneider S, Vallon V, Osswald H, Muhlbauer B.
Postglomerular vasoconstriction induced by dopamine D(3) receptor
activation in anesthetized rats. Am J Physiol Renal Physiol. 2000; 278:
42.
43.
44.
45.
46.
F570–F575
Majewski H, Tung LH, Rand MJ. Adrenaline-induced hypertension in
rats. J Cardiovasc Pharmacol. 1981; 3: 179–185
Majewski H, Tung LH, Rand MJ. Adrenaline activation of prejunctional
beta-adrenoceptors and hypertension. J Cardiovasc Pharmacol. 1982; 4:
99–106
Marullo S, Emorine LJ, Strosberg AD, Delavier-Klutchko C. Selective
binding of ligands to beta 1, beta 2 or chimeric beta 1/beta 2-adrenergic
receptors involves multiple subsites. EMBO J. 1990; 9: 1471–1476
Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the
effects of modest weight reduction. Obes Res. 2000; 8: 270–278
Michel MC, Galal O, Stoermer J, Bock KD, Brodde OE. Alpha- and betaadrenoceptors in hypertension. II. Platelet alpha 2- and lymphocyte beta 2adrenoceptors in children of parents with essential hypertension. A model
for the pathogenesis of the genetically determined hypertension. J
47.
48.
49.
50.
51.
Cardiovasc Pharmacol. 1989; 13: 432–439
Michel MC, Philipp T, Brodde OE. Alpha- and beta-adrenoceptors in
hypertension: molecular biology and pharmacological studies. Pharmacol
Toxicol. 1992; 70: S1–10
Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine
receptors: from structure to function. Physiol Rev. 1998; 78: 189–225
Molinoff PB. Alpha- and beta-adrenergic receptor subtypes properties,
distribution and regulation. Drugs. 1984; 28 Suppl 2: 1–15
Motomura S, Schnepel B, Seher U, Michel MC, Brodde OE. Properties of
alpha 2-adrenoceptors in human myometrium and kidney: similarities with
human platelets, but differences in the rat kidney. J Hypertens Suppl.
1989; 7: S50–S51
Muhlbauer B, Kuster E, Luippold G. Dopamine D(3) receptors in the rat
kidney: role in physiology and pathophysiology. Acta Physiol Scand.
2000; 168: 219–223
52.
53.
54.
55.
56.
Naruse M, Naruse K, Yoshimoto T, Tanaka M, Tanabe A, Imaki T,
Shibasaki T, Demura R, Demura H. Dopaminergic regulation of
aldosterone secretion: its pathophysiologic significance in subsets of
primary aldosteronism. Hypertens Res. 1995; 18 Suppl 1: S59–S64
O'Connell DP, Botkin SJ, Ramos SI, Sibley DR, Ariano MA, Felder RA,
Carey RM. Localization of dopamine D1A receptor protein in rat kidneys.
Am J Physiol. 1995; 268: F1185–F1197
Os I, Kjeldsen SE, Westheim A, Aakesson I, Norman N, Enger E,
Hjermann I, Eide I. Decreased central dopaminergic activity in essential
hypertension. J Hypertens. 1987; 5: 191–197
Pettinger WA, Gandler T, Sanchez A, Saavedra JM. Dietary sodium and
renal alpha 2-adrenergic receptors in Dahl hypertensive rats. Clin Exp
Hypertens A. 1982a; 4: 819–828
Pettinger WA, Sanchez A, Saavedra J, Haywood JR, Gandler T, Rodes T.
Altered renal alpha 2-adrenergic receptor regulation in genetically
57.
58.
59.
60.
61.
hypertensive rats. Hypertension. 1982b; 4: 188–192
Rand MJ, Majewski H. Adrenaline mediates a positive feedback loop in
noradrenergic transmission: its possible role in development of
hypertension. Clin Exp Hypertens A. 1984; 6: 347–370
Rossi NF. Dopaminergic control of angiotensin II-induced vasopressin
secretion in vitro. Am J Physiol. 1998; 275: E687–E693
Rumantir MS, Jennings GL, Lambert GW, Kaye DM, Seals DR, Esler
MD. The 'adrenaline hypothesis' of hypertension revisited: evidence for
adrenaline release from the heart of patients with essential hypertension. J
Hypertens. 2000; 18: 717–723
Saito I, Itsuji S, Takeshita E, Kawabe H, Nishino M, Wainai H, Hasegawa
C, Saruta T, Nagano S, Sekihara T. Increased urinary dopamine excretion
in young patients with essential hypertension. Clin Exp Hypertens. 1994;
16: 29–39
Sanada H, Jose PA, Hazen-Martin D, Yu PY, Xu J, Bruns DE, Phipps J,
62.
63.
64.
65.
Carey RM, Felder RA. Dopamine-1 receptor coupling defect in renal
proximal tubule cells in hypertension. Hypertension. 1999; 33: 1036–1042
Sato M, Soma M, Nakayama T, Kanmatsuse K. Dopamine D1 receptor
gene polymorphism is associated with essential hypertension.
Hypertension. 2000; 36: 183–186
Saxena PR. Interaction between the renin-angiotensin-aldosterone and
sympathetic nervous systems. J Cardiovasc Pharmacol. 1992; 19 Suppl 6:
S80–S88
Shigetomi S, Buu NT, Kuchel O. Dopaminergic abnormalities in
borderline essential hypertensive patients. Hypertension. 1991; 17: 997–
1002
Starke K. Grundlagen der Pharmakologie des Nervensystems. In: Forth W,
Henschler D, Rummel W, Förstermann U, Starke K "Allgemeine und
spezielle Pharmakologie und Toxikologie" Urban Fischer Verlag, 2001, pp
111–146
66.
67.
68.
69.
70.
71.
Thomas GN, Tomlinson B, Critchley JA. Modulation of blood pressure
and obesity with the dopamine D 2 receptor gene TaqI polymorphism.
Hypertension. 2000; 36: 177–182
Vaughan CE, van den Buuse M, Roland BL. Brain dopamine D 2 receptor
mRNA levels are elevated in young spontaneously hypertensive rats.
Neurosci Res. 1999; 34: 199–205
Velasco M, Contreras F, Cabezas GA, Bolivar A, Fouillioux C, Hernandez
R. Dopaminergic receptors: a new antihypertensive mechanism. J
Hypertens. 2002; 20 Suppl 3: S55–S58
Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil
N, Fowler JS. Brain dopamine and obesity. Lancet. 2001; 357: 354–357
Williams GH, Gordon MS, Stuenkel CA, Conlin PR, Hollenberg NK.
Dopamine and nonmodulating hypertension. Am J Hypertens. 1990; 3:
112S–115S
Yoshizumi M, Kitagawa T, Hori T, Katoh I, Houchi H, Ohuchi T, Oka M.
Physiological significance of plasma sulfoconjugated dopamine in patients
with hypertension–clinical and experimental studies. Life Sci. 1996; 59:
324–330
Literatur zu Kap. 14.3
1.
Abhold RH, Sullivan MJ, Wright JM, Harding JW (1987) Binding,
degradation and pressor activity of angiotensin II and III after amino
peptidase inhibition with amastatin and bestatin. J Pharmacol Exp Ther
242: 957–962
2.
Aceto JF, Baker KM (1990) [Sar1] angiotensin II receptor-mediated
stimulation of protein synthesis in chick heart cells. Am J Physiol 258:
H806-H813
3.
Admiraal PJJ, Danser AHJ, Sjoukje-Jong M, Pieterman H, Derkx FHM,
Schalekamp MADH (1993) Regional angiotensin II production in essential
hypertension and renal artery stenosis. Hypertension 21: 173–184
4.
Ahmed A, Li XF, Shams M, Gregory J, Rollason T, Barnes NM, Newton
JR (1995) Localization of the angiotensin II and its receptor subtype
expression in human endometrium and identification of a novel highaffinity angiotensin II binding site. J Clin Invest 96: 848–857
5.
6.
7.
8.
9.
Alhenc-Gelas F, Soubrier F, Hubert C, Allegrini J, Corvol P (1989) The
peculiar characteristics of the amino acid sequence of angiotensin I
converting enzyme, as determined by cDNA cloning of the human
endothelial enzyme. J Cardiovasc Pharmacol 14[suppl. 4]: S6–S9
Ames RP, Borkowski AJP, Sicinski ALMM, Laragh JH (1965) Prolonged
infusions of angiotensin II and norepinephrine on blood pressure,
electrolyte balance, aldosterone and cortisole secretion in normal man in
cirrhosis with ascites. J Clin Invest 44: 1171–1186
Anderson PW, Do YS, Hsueh WA (1993) Angiotensin II causes mesangial
cell hypertrophy. Hypertension 21: 29–35
Andre P, Schott C, Nehlig H, Stoclet JC (1990) Aortic smooth muscle
cells are able to convert angiotensin I to angiotensin II. Biochem Biophys
Res Commun 173: 1137–1142
Ayers CR (1967) Plasma renin activity and renin substrate concentration
in patients with liver disease. Circ Res 20: 594–598
10.
11.
12.
13.
14.
Bachmann S, Peters J, Engler E, Ganten D, Mullins JJ (1992) Transgenic
rats carrying the mouse renin gene. Morphological characterization of a
low-renin hypertension model. Kidney Int 41: 24–36
Baker KM, Booz GW, Dostal DE (1992) Cardiac actions of angiotensin II:
role of an intracardiac renin- angiotensin system. Ann Rev Physiol 54:
227–241
Bauer PH, Chiu AT, Garrison JC (1991) DuP 753 can antagonize the
effects of angiotensin II in rat liver. Mol Pharmacol 39: 579–585
Bellucci A, Wilkes BM (1984) Mechanism of sodium modulation of
glomerular angiotensin receptors in the rat. J Clin Invest 74: 1593–1600
Benjamin N, Collier JG, Webb DJ (1988) Angiotensin II augments
sympathetically induced venoconstriction in man. Clin Sci 5 [suppl. 4]:
337–340
15.
16.
17.
18.
19.
20.
Berk BC, Vekshtein V, Gordon HM, Tsuda T (1989) Angiotensin IIstimulated protein synthesis in cultured vascular smooth muscle cells.
Hypertension 13: 305–314
Bernstein KE, Martin BM, Bernstein EA, Linton J, Striker L, Striker G
(1988) The isolation of angiotensin converting enzyme cDNA. J Biol
Chem 263: 11021–11024
Bernstein KE, Martin BM, Edwards AS, Berstein EA (1989) Mouse
angiotensin converting enzyme is a protein composed of two homologous
domains. J Biol Chem 264: 11945–11951
Bickerton RK, Buckley JP (1961) Evidence for a central mechanism in
angiotensin-induced hypertension. Proc Soc Exp Biol Med 106: 834
Blalock A, Levy SE (1937) Studies of the etiology of hypertension. Ann
Surg 106: 826–847
Blume A, Lebrun CJ, Herdegen T, Linz W, Bravo R, Möllenhoff E, Unger
T (1997) Angiotensin II induces an increased expression of inducible
21.
22.
23.
24.
25.
transcription factors in the brain of spontaneously hypertensive rats.
Hypertension, in press
Blundell T, Sibanda BL, Pearl L (1983) Three dimensional structure,
specificity and catalytic mechanism of renin. Nature 304: 273–275
Bock KD, Gross F (1961) Renin and angiotensin tachyphylaxis. Circ Res
9: 1044–1055
Boer PH, Ruzicka M, Lear W, Harmsen EEF, Rosenthal J, Leenen FHH
(1994) Stretch-mediated activation of cardiac renin gene. Am J Physiol
267: H1630-H1636
Bottari SP, King IN, Reichlin IS, Dahlstroem I, Lyden N, deGasparo M
(1992) The angiotensin AT2 receptor stimulates protein tyrosine
phosphatase activity and mediates inhibition of particulate guanylate
cyclase. Biochem Biophys Res Commun 183: 206–211
Braun-Menendez E, Fasciolo JC, Leloir JF, Munoz JM. The substance
causing renal hypertension. J Physiol 98: 283–298
26.
27.
28.
29.
30.
Brechler V, Jones PW, Levens NR, deGasparo M, Bottari SP (1993)
Agonistic and antagonistic properties of angiotensin analogs at the AT2
receptor in PC12 W cells. Regul Pept 44: 207–213
Brechler V, Reichlin S, de Gasparo M, Bottari SP (1994) Angiotensin II
stimulates protein phosphatase activity through a G-protein independent
mechanism. Receptors and Channels 2: 89–97
Bruneval P, Hinglais N, Alhenc-Gelas F (1986) Angiotensin I converting
enzyme in human intestine and kidney. Ultrastructural
immunohistochemical localization. Histochem 85: 73–80
Buisson B, Bottari SP, de Gasparo M, Gallo-Payet N, Payet MD (1992)
The angiotensin AT2 receptor modulates T-type calcium current in nondifferentiated NG 108–15 cells. FEBS Lett309: 161–164
Buisson B, Laflamme L, Bottari SP, de Gasparo M, Gallo-Payet N, Payet
MD (1995) A G-protein is involved in the angiotensin AT2 receptor
31.
32.
33.
34.
inhibition of the T-type Ca2+ current in non-differentiated NG 108–15
cells. J Biol Chem 270: 1670–1674
Bumpus FM, Catt KJ, Chiu AT (1991) Nomenclature for angiotensin
receptors. A report of the nomenclature committee of the Council for High
Blood Pressure Research. Hypertension 17: 720–722
Burnham CE, Hawel-Johnson CL, Frank BM, Lynch KR (1987)
Molecular cloning of rta renin cDNA and its gene. Proc Natl Acad Sci
USA 84: 5605–5609
Burt DW, Beecroft LJ, Mullind JJ (1985) Mouse renin gene structure,
evolution and function. In: Kosta V, ed. Aspartic proteinases and their
inhibitors. Berlin: Walter de Gruyter & Co: 355–377
Caldwell PRB, Seegal BC, Hsu KC, Das M, Soffer RL (1976) Angiotensin
converting enzyme: vascular endothelial localization. Science 191: 1050–
1051
35.
36.
37.
38.
39.
Cambien F, Poirier O, Lecerf L (1992) Deletion polymorphism in the gene
for angiotensin converting enzyme is a potent risk factor for myocardial
infarction. Nature 359: 641–644
Campbell DJ, Bouhnik J, Menard J, Corvol P (1984) Identity of
angiotensinogen precursors in rat brain and liver. Nature 308: 206–208
Campell DJ, Habener JF (1986) Angiotensinogen gene is expressed and
differenzially regulated in multiple tissues of the rat. J Clin Invest 78: 31–
39
Campbell DJ, Habener DF (1987) Cellular localization of angiotensinogen
gene expression in brown adipose tissue and mesentery: quantification of
messenger ribonucleic acid abundance using hybridization in situ.
Endocrinology 121: 1616–1626
Campbell DJ (1987) Circulating and tissue angiotensin systems. J Clin
Invest 79: 1–6
40.
41.
42.
43.
44.
45.
Campbell-Boswell M, Robertson AL (1981) Effects of angiotensin II and
vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol 35:
265
Carretero O, Gross F (1967) Renin substrate in plasma under various
experimental conditions in the rat. Am J Physiol 213: 695–700
Cassis LA, Lynch KR, Peach MJ (1988) Localization of angiotensinogen
messenger RNA in rat aorta. Circ Res 62: 1259–1262
Cassis LA, Saye JA, Peach MJ (1988) Location and regulation of rat
angiotensinogen messenger RNA. Hypertension 11: 591–596
Chai SY, McKinley MJ, Mendelsohn FAO (1987) Distribution of
angiotensin converting enzyme in sheep hypothalamus and medulla
oblongata visualized by in vitro autoradiography. Clin Exper Theory and
Practice A9(2&3): 449–460
Chang RSL, Lotti VJ (1989) Selective ligands reveal subtypes of
angiotensin receptors in rat vasculature and brain. Pharmacologist 31: 150
46.
47.
48.
49.
50.
Chang RSL, Lotti VL (1990) Two distinct angiotensin II receptor binding
sites in rat adrenal revealed by new selective nonpeptide lgands. Mol
Pharmacol 29: 347–351
Chang RSL, Lotti VJ (1991) Angiotensin receptor subtypes in rat, rabbit
and monkey tissues: relative distribution and species dependency. Life Sci
49: 1485–1490
Chappell MC, Diz DI, Jacobson DW (1992) Pharmacological
characterization of angiotensin II binding sites in the canine pancreas.
Peptides 13: 313–318
Chiu AT, Herblin WF, McCall DE (1989) Identification of angiotensin II
receptor subtypes. Biochem Biophys Res Commun 165: 196–203
Chiu AT, Duncia JV, McCall DE (1989) Nonpeptide angiotensin II
receptor antagonists. III. Structure function studies. J Pharmacol Exp Ther
250: 867–874
51.
52.
53.
54.
55.
Chung O, Rohmeiss P, Gretz N, Unger Th The transgenic mRen2 rat. In:
Gretz N, Strauch M eds. Experimental and genetic rat models of chronic
renal failure. Basel: Karger: 124–128
Chung O, Schips T, Qadri F, Ganten D, Mullins JJ, Unger Th (1991)
Cardiovascular characterization of a new hypertensive animal model. J
Hypertens 9 [suppl. 6]: S340
Clouston WM, Evans BA, Haralambidis J, Richards RI (1988) Molecular
cloning of the mouse angiotensinogen gene. Genomics 2: 240–248
Cogan MG (1990) Angiotensin II: a powerful controller of sodium
transport in the early proximal tubule. Hypertension 13: 451–458
Correa FMA, Plunkett LM, Saavedra JM, Hichens M (1985) Quantitative
autoradiographic determination of angiotensin converting enzyme
(kininase II) binding and individual rat brain nuclei with 125I-351A, a
specific enzyme inhibitor. Brain Res 347: 192–195
56.
57.
58.
59.
60.
Darnell JE, Kerr IA, Stark GR (1994) Jak/STAT pathways and
transcriptional activation in response to IFNs and other extracellular
signaling proteins. Science 264: 1415–1421
Deschepper CF, Bouhnik J, Ganong WF (1986) Colocalization of
angiotensinogen and glial fibrillary acidic protein in astrocytes in rat brain.
Brain Res 355: 195
Dhanaraj V, Dealwis CG, Frazao C (1992) X-ray analysis of peptideinhibitor complexes define the structural basis of specificity for human and
mouse renins. Nature 357: 466–472
Dostal DE, Rothblum KN, Chernin MI, Cooper GR, Baker KM (1992)
Intracardiac detection of angiotensinogen and renin: a localized reninangiotensn system in neonatal rat heart. Am J Physiol 263: C838- C850
Dudley DT, Panek RL, Major TC (1990) Subclasses of angiotensin II
binding sites and their functional significance. Mol Pharmacol 38: 370–
377
61.
62.
63.
64.
65.
Dudley DT, Hubbel SE, Summerfelt RM (1991) Characterization of
angiotensin II (AT2) binding sites in R3T3 cells. Mol Pharmacol 40: 360–
367
Dzau VJ (1984) Vascular renin angiotensin: a possible autocrine or
paracrine system in control of vascular function. J Cardiovasc Pharmacol
6: S377–S382
Dzau VJ, Ellison KE, Brody T, Ingelfinger JR, Pratt RE (1987) A
comparative study of the distribution of renin and angiotensinogen
messenger ribonucleic acids in rat and mouse tissues. Endocrinology 120:
2334–2338
Dzau VJ, Rosenthal J, Swales JD (1987) Vascular renin – A consensus
view. J Hypertens 5 (suppl2): S77- S78
Dzau VJ (1988) Cardiac renin-angiotensin system: molecular and
functional aspects. Am J Med 84 [suppl. 3A]: 22–27
66.
67.
68.
69.
70.
71.
Dzau VJ (1988) Circulating vs. local renin angiotensin systems in
cardiovascular homeostasis. Circulation 77 [suppl. I]: I4-I13
Dzau VJ, Gibbons GH, Pratt RE (1991) Molecular mechanisms of
vascular renin-angiotensin system in myointimal hyperplasia.
Hypertension 18 [suppl. II]: II100-II105
Eggena P, Krall F, Egena MP, Clegg K, Fittingoff M, Barrett JD (1990)
Production of angiotensinogen by cultured rat aortic smooth muscle cells.
Clin Exper Hyper Theory and Practice A12(7): 1175–1189
Eggena P, Zhu JH, Clegg K, Barrett JD (1993) Nuclear angiotensin
receptors transduce transcription of renin and angiotensin mRNA.
Hypertension 22: 496–501
Egleme C, Cressier F, Wood JM (1990) Local formation of angiotensin II
in the rat aorta: effect of endothelium. Br J Pharmacol 100: 237–240
Eglen RM, Rapp JM, Leung E (1991) Characterization of angiotensin II
receptors in guinea pig gastriintestinal tract. FASEB J 5: A869
72.
73.
74.
75.
76.
77.
Ehlers MRW, Riordan JF (1989) Angiotensin converting enzyme: new
concepts concerning its biological role. Biochemistry 28: 5311–5318
Elton TS, Stephan TC, Taylor GR (1992) Isolation of two distinct type 1
angiotensin II receptor genes. Biochem Biophys Res Commun 184: 1067–
1073
Entzeroth M, Hadamovsky S (1991) Angiotensin II receptors in the rat
lung are of the AII-1 subtype. Eur J Pharmacol 206: 237–241
Erdös EG (1975) Angiotensin I converting enzyme. Circ Res 36: 247–253
Erdös EG (1990) Angiotensin I converting enzyme and the changes in our
concepts through the year. Hypertension 16: 363–370
Ernsberger P, Zhou J, Damon TH, Douglas JG (1992) Angiotensin II
receptor subtypes in cultured rat renal mesangial cells. Am J Physiol 263:
F411-F416
78.
79.
80.
81.
82.
Falkenhahn M, Franke F, Bohle RM, Zhu YZ, Stauss HM, Bachmann S,
Danilov S, Unger Th (1994) Cellular distribution of angiotensinconverting enzyme after myocardial infarction. Hypertension 25: 219–226
Fischer J, Stoll M, Unger Th (1996) Thrombospondin mRNA expression
is increased in endothelial cells following stimulation of AT2 receptors
(abstract). J Vasc Res 33(S1): 26
Freer RJ, Pappano AJ, Peach MJ (1976) Mechanisms for the positive
inotropic effect of angiotensin II on isolated cardiac muscle. Circ Res 39:
178
Fukamizu A, Nishi K, Cho T (1988) Structure of the rat renin gene. J Mol
Biol 201: 443–450
Furuta H, Guo DF, Inagami T (1992) Molecular cloning and sequencing of
the gene encoding human angiotensin II type 1 receptor. Biochem Biophys
Res Commun 183: 8–13
83.
84.
85.
86.
87.
Fyhrquist FY, Forslund T, Tikkanen I, Grönhagen-Riska C (1980)
Induction of angiotensin-I converting enzyme in rat lung with captopril
(SQ 14225). Eur J Pharmacol 67: 473–475
Gaillard I, Clauser E, Corvol P (1989) Structure of human angiotensinogen
gene. DNA 8: 87–99
Ganten D, Schelling P, Flugel RM, Ganten U (1975) Effect of angiotensin
and an angiotensin antagonist on iso-renin and cell-growth in 3T3 mouse
cells. Int Res Commun Med Sci 3: 327
deGasparo M, Whitebread S, Mele M (1990) Biochemical characterization
of two angiotensin II receptor subtypes in the rat. J Cardiovasc Pharmacol
16 [suppl. 4]: S31–S35
Gehlert DR, Gackenheimer SL, Reel JK, Lin HS, Steinberg MI (1990)
Non-peptide angiotensin II receptor antagonists discriminate subtypes of
125I-angiotensin II binding sites in the rat brain. Eur J Pharmacol 187:
123–126
88.
89.
90.
91.
92.
Gehlert DR, Gachenheimer SL, Schober DA (1991) Autoradiographic
localization of subtypes of angiotensin II antagonist binding in the rat
brain. Neurosci 44: 501–514
Geisterfer AAT, Peach MJ, Owens GK (1988) Angiotensin II induces
hypertrophy, not hyperplasia of cultured rat aortic smooth muscle cells.
Circ Res 62: 749–756
Gohlke P, Bünning P, Unger T (1992) Distribution and metabolism of
angiotensin I and II in the blood vessel wall. Hypertension 20: 151–157
Goldblatt H, Lynch J, Hanzal RF, Summervill WW (1934) The production
of persistent elevation of systolic blood pressure by means of renal
ischemia. J Exp Med 59: 347–379
Gomez RA, Lynch KR, Chevalier RL (1988) Renin and angiotensinogen
gene expression in maturing rat kidney. Am J Physiol 254: F582-F587
93.
94.
95.
96.
97.
Gomez RA, Lynch KR, Chevalier RL (1988) Renin and angiotensinogen
expression and intrarenal renin distribution during ACE inhibtion. Am J
Physiol 254: F900-F906
Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE (1991)
Expression of AT2 receptors in the developing rat fetus. J Clin Invest 88:
921–933
Greene LA, Tischler AS (1982) PC12 pheochromocytoma cultures in
neurobiological research. Adv Cell Neurobiol 3: 373–414
Griffin SA, Brown WCB, MacPherson F (1991) Angiotensin II causes
vascular hypertrophy in part by a non-pressor mechanism. Hypertension
17: 626–635
Grinstead WC, Young JB (1992) The myocardial renin-angiotensin
system: existence, importance and clinical implications. Am Heart J 123:
1039–1045
98.
99.
100.
101.
102.
Gross F (1958) Renin and hypertension, physiologische und
pathophysiologische Wirkstoffe. Klin Wochenschr 36: 693–705
Guillot FL, Augus KL (1990) Angiotensin peptide regulation of fluidphase endocytosis in brain microvessel endothelial cell monolayers. J
Cereb Blood Flow Metab 10: 827–834
Hackenthal E, Paul M, Ganten D, Taugner R (1990) Morphology,
physiology and molecular biology of renin secretion. Physiol Rev 70:
1067–1116
Harding JW, Jenses LL, Hanesworth JM, Roberts KA, Page TA, Wright
JW (1992) Release of angiotensin in paraventricular nucleus of rat in
response to physiological and chemical stimuli. Am J Physiol 262: F17F23
Harding JW, Wright JW, Swanson GN, Hanesworth JM, Krebs LT (1994)
AT4 receptors: specificity and distribution. Kid Int 46: 1510–1512
103.
104.
105.
106.
107.
Hardman JA, Hort YJ, Carazaro DF (1984) Primary structure of the
human renin gene. DNA 3: 457–467
Herblin WF, Diamond SM, Timmermans PBMWM (1991) Localization of
angiotensin II receptor subtypes in the rabbit adrenal and kidney. Peptides
12: 581–584
Herblin WF, Chiu AT, McCall DE (1991) Angiotensin II receptor
heterogeinity. Am J Hypertens 4: 299S- 302S
Hilbert P, Lindpaintner K, Beckmann JS (1991) Chromosomal mapping of
two genetic loci associated with blood-pressure regulation in hereditary
hypertensive rats. Nature 353: 521–529
Hodsman GP, Kohzuki M, Howes LG, Sumithran E, Tsunoda K, Johnston
CI (1988) Neurohumoral responses to chronic myocardial infarction in
rats. Circulation 78: 376–381
108.
109.
110.
111.
112.
Höhle S, Spitznagel H, Rascher W, Culman J, Unger Th (1995)
Angiotensin AT1 receptor-mediated vasopressin release and drinking are
potentiated by an AT2 receptor antagonist. Eur J Pharmacol 275: 277–282
Höhle S, Culman J, Boser M, Qadri F, Unger Th (1996) Effect of
angiotensin AT2 and muscarinic receptor blockade on osmotically induced
vasopressin release. Eur J Pharmacol 300: 119–123
Hogarty DC, Speakman EA, Puig V, Phillips MI (1992) The role of
angiotensin AT1 and AT2 receptors in the pressor, drinking and
vasopressin responses to central angiotensin. Brain Res 586: 289–294
Holm I, Ollo R, Panthier JJ, Rougeon F (1984) Evolution of aspartyl
proteases by gene duplication: the mouse renin gene is organized in two
homologous clusters of four exons. EMBO J 3: 557–562
Hooper NM (1991) Angiotensin converting enzyme: implications from
molecular biology for its physiological functions. Int J Biochem 23: 641–
647
113.
114.
115.
116.
117.
Hsueh WA, Carlson EJ, Israel-Hagman M (1981) Mechanism of acid
activation of renin: role of kallikrein in kinin activation. Hypertension
3[suppl. I]: I22-I29
Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM (1984)
Role of angiotensin II in the altered renal function of congestive heart
failure. Circ Res 55: 669–675
Ichiki T, Herold CL, Kambayashi Y, Bardhan S, Inagami T (1994)
Cloning of the cDNA and the genomic structure of the mouse angiotensin
II type 2 receptor. Biochim Biophy Acta 1189: 247–250
Ikemoto F, Song GB, Tominaga M, Kanayama Y, Yamamoto K (1987)
Angiotensin converting enzyme predominates in the inner cortex and
medulla of the rat kidney. Biochem Biophys Res Commun 144: 915–921
Ikemoto F, Song GB, Tominaga M, Kanayama Y, Yamamoto K (1990)
Angiotensin converting enzyme in the rat kidney. Activity, distribution
118.
119.
120.
121.
and response to angiotensin converting enzyme inhibitors. Nephron 55
[suppl. 1]: 3–9
Imboden H, Harding JW, Hilgenfeldt U, Celio MR, Felix D (1987)
Localization of angiotensinogen in multiple cells types of rat brain. Brain
Res 410: 74–77
Ingelfinger JR, Fon EA, Ellison KE, Dzau VJ (1988) Localization of the
intrarenal renin angiotensin system (RAS) by in situ hybridization of renin
and angiotensinogen mRNAs. [abstract]. Kidney Int 33: 269A
Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ (1990) In situ
hybridization evidence for angiotensinogen messenger RNA in the rat
proximal tubule. An hypothesis for the intrarenal angiotensin system. J
Clin Invest 85: 417–423
Jacobsen J, Poulsen K (1990) In vivo generation and elimination of
angiotensin in the rat. Clin Exp Pharamcol Physiol 17: 445–451
122.
123.
124.
125.
126.
127.
Jeunemaitre X, Soubrier F, Koteletsev YV (1992) Molecular basis of
human hypertension: role of angiotensinogen. Cell 71: 169–180
Jin M, Wilheml MJ, Lang RE, Unger Th, Lindpaintner K, Ganten D
(1988) Endogenous tissue renin- angiotensin systems: from molecular
biology to therapy. Am J Med 84: [suppl. 3A]: 28–36
Johnson H, Drummer OH (1988) Hydrolysis of angiotensin I by peptidase
in homogenates of rat lung and aorta. Biochem Pharmacol 37: 1131–1136
Johnston CI, Burrell LM, Perich R, Jandeleit K, Jackson B (1992) The
tissue renin-angiotensin system and its functional role. Clin Exp
Pharmacol Physiol 19[suppl. 19]: 1–5
Kageyama R, Ohkubo H, Nakanishi S (1984) Primary structure of human
preangiotensinogen deduced from the cloned cDNA sequence.
Biochemistry 23: 3603–3609
Kambayashi Y, Bardhan S, Tahahashi K, Tsuzuki S, Inui H, Hamakubo T,
Inagami T (1993) Molecular cloning of a novel angiotensin II receptor
128.
129.
130.
131.
isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem
268: 24543–24546
Kang J, Posner P, Sumners C (1994) Angiotensin type II receptor
stimulation of neuronal K+ currents involves an inhibitory G-protein. Am
J Physiol 267: C1289-C1297
Kawahara Y, Sunako M, Tsuda T, Fukuzaki H, Fukumoto Y, Takai Y
(1988) Angiotensin II induces expression of the c-fos gene through protein
kinase C activation and calcium ion mobolization in cultured vascular
smooth muscle cells. Biochem Biophys Res Commun 150: 52–59
Khairallah PA, Robertson AL, Davila D (1972) Effects of angiotensin II
on DNA, RNA and protein synthesis. In: Genest J, Kolw E, eds.
Hypertension. New York: Springer Verlag: 212–220
Kimura B, Sumners C, Phillips MI (1992) Changes in skin angiotensin II
receptors in rats during wound healing. Biochem Biophys Res Commun
187: 1083–1090
132.
133.
134.
135.
136.
Kinoshita A, Urata H, Bumpus FM, Husain A (1991) Multiple
determinates for the high substrate specificity of an angiotensin II forming
chymase from the human heart. J Biol Chem 266(29): 19192–19197
Kitami Y, Hiwada K, Kokubu T (1989) Kidney renin gene expression in
spontaneously hypertensive rats. J Hypertens 7: 727–731
Klett C, Hellman W, Suzuki F (1988) Induction of angiotensinogen
mRNA in hepatocytes by angiotensin II and glucocorticoids. Clin Exp
Hypertens A10: 1009–1022
Kobayashi M, Furkawa Y, Chiba S (1978) Positive chronotropic and
inotropic effects of angiotensin II in the dog heart. Eur J Pharmacol 50: 17
Kofir I, Dzau VJ (1987) Endothelial renin-angiotensin pathway: evidence
for intracellular synthesis and secretion of angiotensins. Circ Res 60: 422–
428
137.
138.
139.
140.
141.
Kohara K, Brosnihan KB, Chappell MC, Khosla MC, Ferrario CM (1991)
Angiotensin (1–7): a member of circulating angiotensin peptides.
Hypertension 17: 131–138
Koike G, Winer ES, Horiuchi M, Brown DM, Szpires C, Dzau VJ, Jacob
HJ (1995) Cloning, characterization and genetic mapping of the rat type 2
angiotensin II receptor gene. Hypertension 26(6): 998–1002
Kost CK Jr., Jackson EK (1993) Enhanced renin angiotensin II subtype 1
receptor responses in the spontaneously hypertensive rat. Hypertension 21:
420–431
Krivoy N, Schlüter H, Karas M, Zidek W (1992) Generation of
angiotensin II from human plasma by kallikrein. Clin Sci 83: 477–482
Lang RE, Rascher W, Heil J, Unger Th, Wiedemann G, Ganten D (1981)
Angiotensin stimulates oxytocin release. Life Sci 29: 1425–1428
142.
143.
144.
145.
146.
Langford KG, Shai SY, Howard TE, Kovac MJ, Overbeek PA, Bernstein
KE (1991) Transgenic mice demonstrate a testis.specific promoter for
angiotensin converting enzyme. J Biol Chem 266: 15559–15562
Lecki BJ, McGhee NK (1980) Reversible activation -inactivation of renin
in human plasma. Nature 288: 702–704
Lebrun CJ, Bao G, Möllenhoff E, Culman J, Unger Th (1995) Angiotensin
II induces the expression of c- fos mRNA in the central nervous system of
the rat. Clin Exp Hyper 17: 877–893
Lebrun C, Blume A, Herdegen T, Seifert K, Bravo R, Unger Th (1995)
Angiotensin II induces a complex activation of transcription factors in the
rat brain: expression of Fos, Jun and Krox proteins. Neurosci 65: 93–99
Leung KH, Smith RD, Timmermans PBMWM, Chiu AT (1991) Regional
distribution of the two subtypes of angiotensin II receptor in rat brain
using selective non-peptide antagonists. Neurosci Lett 123: 95–98
147.
148.
149.
150.
151.
Lindpaintner K, Wilhelm MJ, Manwen J (1987) Tissue renin-angiotensin
systems: focus on the heart. J Hypertens 5 [suppl. 2]: S33–S38
Lindpaintner K, Jin M, Niedermeyer N, Wilhelm MJ, Ganten D (1990)
Cardiac angiotensinogen and its local activation in the isolated perfused
beating heart. Circ Res 67: 564–573
Lu D, Raizada MK (1995) Delivery of angiotensin II type 1 receptor
antisense inhibits angiotensin action in neurons from hypertensive rat
brain. Proc Natl Acad Sci USA 92: 2914–2918
Lüscher TF, Boulanger CM, Dohi Y, Yang Z (1992) Endothelium-derived
contacting factors. Hypertension 19: 117–130
Lyall F, Dornan ES, McQueen J, Boswell F, Kelly M (1992) Angiotensin
II increases protooncogene expression and phosphoinositide turnover in
vascular smooth muscle cells via angiotensin AT1 receptor. J Hypertens
10: 1463–1469
152.
153.
154.
155.
156.
Lynch KR, Peach MJ (1991) Molecular biology of angiotensinogen.
Hypertension 17: 263–269
Malik KU, Nasjletti A (1976) Facilitation of adrenergic transmission by
locally generated angiotensin II in rat mesenteric arteries. Circ Res 38: 26–
30
Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Deleafontaine
P, Bernstein KE (1995) Direct stimulation of Jak/STAT pathway by the
angiotensin II AT1 receptor. Nature 375: 247–250
Marshall JJ, Konros HA (1990) Endothelium-derived relaxing factors. A
perspective from in vivo data. Hypertension 16: 371–386
Martin MM, Su B, Elton TS (1994) Molecular cloning of the human
angiotensin II type 2 receptor cDNA. Biochem Biophys Res Commun
205(1): 645–651
157.
158.
159.
160.
161.
Menard J, Bouhnik J, Clauser E, Richoux JP, Corvol P (1983)
Biochemistry and regulation of angiotensinogen. Clin Exp Hypertens
A5[7&8]: 1005–1019
Mendelsohn FAO, Lloyd CJ, Kachel C, Funder JW (1982) Induction by
glucocorticoids of angiotensin converting enzyme production from bovine
endothelial cells in culture and rat lung in vivo. J Clin Invest 70: 684–692
Metsärinne KP, Stoll M, Gohlke P, Paul M, Unger Th (1992) Angiotensin
II is antimitogenic in vitro for heart capillary endothelial cells. Pharm
Pharmacol Lett 2: 150–152
Millan MA, Jacobowitz DM, Aguilera G, Catt KJ (1991) Differenzial
distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat
brain during development. Proc Natl Acad Sci USA 88: 11440–11444
Mitchell KD, Navar LG (1990) Interactive effects of angiotensin II on
renal hemodynamics and tubular reabsorptive function. Kidney Int 38:
S69–S73
162.
163.
164.
165.
166.
Miyazaki H, Fukamizu A, Hirose S (1984) Structure of the human renin
gene. Proc Natl Acad Sci USA 81: 5999–6003
Moffert RB, McGowan RA, Gross KW (1986) Modulation of kidney renin
messenger RNA levels during experimentally induced hypertension.
Hypertension 8: 874–882
Morduchowicz GA, Sheikh-Hamad D, Dwyer BE, Stern N, Jo OD,
Yanagawa N (1991) Angiotensin II directly increases rabbit renal brushborder membrane sodium transport: presence of local signal transduction
system. J Membrane Biol 122: 43–53
Morris BJ (1989) Human renin protein and gene structures: present and
future targets for a renin blockade in treatment of hypertension. J
Hypertens 7(2): S9–S14
Mullins JJ, Burt DW, Windass JD, McTurk P, George H, Brammar WJ
(1982) Molecular cloning of two distinct renin genes from the DBA/2
mouse. EMBO J 1: 1461–1466
167.
168.
169.
170.
171.
Mullins JJ, Peters J, Ganten D (1990) Fulminant hypertension in
transgenic rat harbouring the mouse mRen-2 gene. Nature 344: 541–544
Mukoyama M, Nakajama M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ
(1993) Expression cloning of type 2 angiotensin II receptor reveals a
unique class of seventransmembrane receptors. J Biol Chem 268: 24539–
24542
Munzenmaier DH, Greene AS (1996) Opposing actions of angiotensin II
on microvascular growth and arterial blood pressure. Hypertension 27:
760–765
Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE
(1991) Isolation of a cDNA encoding the vascular type 1 angiotensin II
receptor. Nature 351: 233–236
Naftilan AJ, Pratt RE, Eldridge CS, Dzau VJ (1989) Angiotensin II
induces c-fos expression in smooth muscle cells via transcriptional control.
Hypertension 13: 706–711
172.
173.
174.
175.
Naftilan AJ, Zuo WM, Ingelfinger JR, Ryan T, Pratt T, Dzau VJ (1991)
Localization and differenzial regulation of angiotensinogen mRNA
expression in the vessel wall. J Clin Invest 87: 1300–1311
Nakajima M, Mukoyama M, Pratt RE, Horiuchi M, Dzau VJ (1993)
Cloning of cDNA and analysis of the gene for the mouse angiotensin II
type 2 receptor. Biochem Biophys Res Commun 197(2): 393–399
Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R,
Zhang L, Horiuchi M, Pratt RE, Dzau VJ (1995) The angiotensin II type 2
(AT2) receptor antagonizes the growth effects of the AT1 receptor: gainof- function study using gene transfer. Proc Natl Acad Sci USA 92(23):
10663–10667
Neuß M, Regitz-Zagrosek V, Fleck E (1994) Human cardiac fibroblasts
express an angiotensin receptor with unusal bindng characteristics.
Biochem Biophys Res Commun 204: 1334–1339
176.
177.
178.
179.
180.
Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M (1995)
Regulation of gene transcription of angiotensin II receptor subtypes in
myocardial infarction. J Clin Invest 95: 46–54
Obermüller N, Unger Th, Culman J, Gohlke P, deGasparo M, Bottari SP
(1991) Distribution of angiotensin II receptor subtypes in rat brain nuclei.
Neurosci Lett 132: 11–15
Oelkers W, Brown JJ, Fraser R (1974) Sensitization of the adrenal cortex
to angiotensin II in sodium- deplete man. Circ Res 34: 69
Ohkubo H, Kageyama R, Ujihara M, Hirose T, Inayama S (1983) Cloning
and sequence analysis of cDNA of rat angiotensinogen. Proc Natl Acad
Sci USA 80: 2196–2200
Okunishi H, Miyazaki M, Okamura T, Toda N (1987) Different
distribution of two types of angiotensin II- generating enzymes in the
aortic wall. Biochem Biophys Res Commun 149: 1186–1192
181.
182.
183.
184.
185.
Oldfield BJ, Ganten D, McKinley MJ (1989) An ultrastructural analysis of
the distribution of angiotensin II in the rat brain. J Neuroendocrinol 1:
121–128
Owens GK, Rabinowitch PS, Schwartz SM (1981) Smooth muscle cell
hypertrophy vs. hyperplasia in hypertension. Proc Natl Acad Sci USA 78:
7759–7763
Page IH, Helmer OM (1940) Angiotensin activator, renin, and angiotonin
inhibitor and the mechanism of angiotonin tachyphylaxis in normal,
hypertensive and nephrectomized animals. J Exp Med 71: 485–519
Page JH, McSwain B, Knapp GM, Andrus WD (1941) Origin of renin
activator. Am J Physiol 135: 214–235
Paguet JL, Baudouin-Legros M, Marchel P, Meyer P (1989) Enhanced
proliferation activity of cultured smooth muscle cells from spontaneously
hypertensive rats. Am J Hypertens 13: 295–304
186.
187.
188.
189.
190.
191.
Paquet JC, Bandomin-Legros M, Brunelle G, Meyer P (1990) Angiotensin
II-induced proliferation of aortic myocytes in spontaneously hypertensive
rats. J Hypertens 8: 565–572
Panthier JJ, Holm I, Rougeon F (1982) The mouse Rn locus: S allele of the
renin regulator gene results from a single structural gene duplication.
EMBO J 1: 1417–1421
Paul M, Printz M, Harms E, Unger Th, Lang RE, Ganten D (1985)
Localization of renin and converting enzyme in nerve endings of rat brain.
Brain Res 334: 315–324
Peach MJ, Cline WH, Watts DT (1966) Release of adrenal catecholamines
by angiotensin II. Circ Res 19: 571–575
Peach MJ (1981) Molecular actions of angiotensins. Biochem Pharamcol
30: 2745–2751
Peters J, Münter K, Bader M, Hackental E, Mullins JJ, Ganten D (1993)
Increased adrenal renin in transgenic hypertensive rats, TGR(mRen2)27,
192.
193.
194.
195.
and its regulation by cAMP, angiotensin II, and calcium. J Clin Invest 91:
742–747
Phillips MJ, Speakman EA, Kimura B (1993) Levels of angiotensin and
molecular biology of the tissue renin-angiotensin systems. Reg Pept 43: 1–
20
Piccini N, Knopf JL, Gross KW (1982) A DNA polymorphism, consistent
with gene duplication, correlated with high renin levels in the mouse
submaxillary gland. Cell 30: 205–213
Pipili E, Manolopoulos V, Carravas J (1989) Angiotensin converting
enzyme activity is present in the endothelium denuded aorta. Br J
Pharmacol 98: 333–335
Pratt RE, Zou WM, Naftilan AJ, Ingelfinger JR, Dzau VJ (1989) Altered
sodium regulation of renal angiotensinogen mRNA in the spontaneously
hypertensive rat. Am J Physiol 256: 469–474
196.
197.
198.
199.
Pucell AG, Hodges JC, Sen I, Bumpus FM, Husain A (1991) Biochemical
properties of the ovarian granulosa cell type 2 angiotensin II receptor.
Endocrinology 128: 1947–1959
Qadri F, Culman J, Veltmar A, Maas K, Rascher W, Unger Th (1993) The
angiotensin II-induced vasopressin release is mediated through alphaadrenoreceptors and angiotensin II AT1 receptors in the supraoptic
nucleus. J Pharmacol Exp Ther 267(2): 567–574
Qadri F, Edling O, Wolf A, Gohlke P, Culman J, Unger Th (1994) Release
of angiotensin in the paraventricular nucleus in response to hyperosmotic
stimulation in conscious rats: a microdialysis study. Brain Res 637: 45–49
Raizada MK, Rydzewski B, Lu D, Sumners C (1993) Angiotensin II type
1 receptor-mediated stimulation of c-fos gene expression in astroglial
cultures. Am J Physiol 265: C1046-C1049
200.
201.
202.
203.
204.
Rasmussen S, Nielson MD, Giese J (1981) Captopril combined with
thiazide lowers renin substrate concentration: implications for
methodology in renin assays. Clin Sci 60: 591–593
Ray PE, Castren E, Ruley EJ, Saveedra JM (1990) Different effects of
sodium or chloride depletion on angiotensin II receptors in rats. Am J
Physiol 258: R1008-R1015
Ray PE, Aguilera G, Kopp JB, Horikoshi S, Klotman PE (1991)
Angiotensin II receptor-mediated proliferation of cultured human fetal
mesangial cells. Kidney Int 40: 764–771
Re R, Fallon JT, Dzau VJ, Quay SC, Haber S (1982) Renin synthesis by
canine aortic smooth muscle cells in culture. Life Sci 30: 99–106
Re RN (1989) The cellular biology of angiotensin: paracrine, autocrine
and intracrine actions in cardiovascular tissues. J Mol Cell Cardiol 21
[suppl. V]: 63–69
205.
206.
207.
208.
Rix E, Ganten D, Schüll B, Unger Th, Taugner R (1981) Converting
enzyme in the choroid plexus, brain and kidney: immunocytochemistry
and biochemical studies in rats. Neurosci Lett 22: 125–130
Roberts KA, Krebs LT, Kramar EA, Shaffer MJ, Harding JW, Wright JW
(1995) Autoradiographic identification of brain angiotensin IV binding
sites and differenzial c-fos expression following intracerebroventricular
injection of angiotensin II and IV in rats. Brain Res 682: 13–21
Rogerson FM, Chai SY, Schlawe I, Murray WK, Marley PD, Mendelsohn
FAO (1992) Presence of angiotensin converting enzyme in the adventitia
of large blood vessels. J Hypertens 10: 615–620
Rohmeiss P, Beyer C, Hocher B, Qadri F, Gretz N, Strauch M, Unger Th
(1995) Osmotically induced natriuresis and blood pressure involves
angiotensin AT1 receptors in the subfornical organ. J Hypertens 13: 1399–
1404
209.
210.
211.
212.
Rohmeiss P, Beyer C, Nagy E, Tschöpe C, Höhle S, Strauch M, Unger Th
(1995) NaCl injections in brain induce natriuresis and blood pressure
responses sensitive to ANG-II AT1 receptors. Am J Physiol 269: F282F288
Rosenthal J, Nowaczynski R, Boucher R, Genest J (1968) Acute changes
in plasma volume, renin activity, and free aldosterone levels in healthy
subjects following furosemide administration. Canad J Physiol Pharmacol
46: 85–91
Rosenthal J, Thurnreiter M, Plaschke M, Geyer M, Reiter W, Dahlheim H
(1990) Reninlike enzymes in human vasculature. Hypertension 15, 6: 848–
853
Rougeon F, Chambraud B, Foote S, Panthier JJ, Nageotte R (1981)
Molecular cloning of a mousesubmaxillary gland renin cDNA fragment.
Proc Natl Acad Sci USA 78: 6367–6371
213.
214.
215.
216.
217.
Rowe BP, Grove KL, Saylor DL, Speth RC (1991) Discrimination of
angiotensin II receptor subtype distribution in the rat brain using nonpeptide receptor antagonists. Regul Pept 33: 45–53
Rowland NE, Li BH, Fregly MJ, Smith GC (1995) Fos induced in brain of
spontaneously hypertensive rats by angiotensin II and colocalization with
AT1 receptors. Brain Res 675: 127–134
Roy SN, Kusari J, Soffer RL, Lai CY, Sen GC (1988) Isolation of cDNA
clones of rabbit angiotensin converting enzyme: identification of twio
distinct mRNAs for the pulmonary and the testicular isoenzymes. Biochem
Biophys Res Commun 155: 678–684
Ryan JW (1989) Peptidase enzymes of the pulmonary vascular surface.
Am J Physiol 257: L53-L60
Samani NJ, Swales JD, Brammar WJ (1988) Expression of renin gene in
extra-renal tissues of the rat. Biochem J 253: 907–910
218.
219.
220.
221.
222.
Samani NJ, Godfrey NP, Major JS, Brammar WJ, Swales JD (1989)
Kidney renin mRNA levels in the early and chronic phases of two kidney,
one clip hypertension in the rat. J Hypertens 7: 105–112
Saveedra JM (1992) Brain and pituitary angiotensin. Endocr Rev 13: 329–
380
Saye JA, Singer HA, Peach MJ (1984) Role of endothelium in conversion
of angiotensin II to angiotensin II in rabbit aorta. Hypertension 6: 216–221
Schelling P, Ganten U, Sponer G, Unger Th, Ganten D (1980)
Components of the renin-angiotensin system in the cerebospinal fluid of
rats and dogs with special consideration of the origin and the fate of
angiotensin II. Neuroendocrinol 31: 297–308
Schinke M, Doods HN, Ganten D, Wienen W, Entzeroth M (1991)
Characterization of rat intestinal angiotensin II receptors. Eur J Pharmacol
204: 165–170
223.
224.
225.
226.
227.
Schunkert H, Hirsch AT, Mankodi S, Talsness C, Dzau VJ, Ingelfinger JR
(1989) Renal angiotensinogen gene expression in experimental heart
failure: effect of angiotensin converting enzyme inhibition (abstract). Clin
Res 37: 584A
Sealey JE, Atlas SA, Laragh JH (1980) Prorenin and other large molecular
weight forms of renin. Endocr Rev 1: 365–392
Sechi LA, Grady EF, Griffin CA, Kalinyak JE, Schambelan M (1992)
Distribution of angiotensin II receptor subtypes in rat and human kidney.
Am J Physiol 262: F236-F240
Seikaly MG, Arant BS Jr, Seney FD (1990) Endogenous angiotensin
concentrations in specific intrarenal fluid compartments of the rat. J Clin
Invest 86: 1352–1357
Shepherd JT, Katusic ZS (1991) Endothelium-derived relaxing factors:
endothelium dependent relaxation. Hypertension 18 [suppl. III]: III76III85
228.
229.
230.
231.
232.
Shimizu K, Share L, Claybaugh JR (1973) Potentiation by angiotensin II
of the vasopressin response to an increasing plasma osmolality.
Endocrinology 93: 42–50
Siemens IR, Reagan LP, Yee DK, Fluharty SJ (1994) Biochemical
characterization of two distinct angiotensin AT2 receptor populations in
murine neuroblastoma N1E-115 cells. J Neurochem 62: 2106–2115
Simon M, Flügge A, Fuchs E, Gröne HJ (1991) Evidence for two
angiotensin II receptor subtypes in human fetal and adult kidney
demonstrated by th eAII receptor antagonist losartan and PD123177.
FASEB J 5: A870
Skeggs LT, Kahn JR, Shumway NP (1956) The preparation and function
of the hypertensive converting enzyme. J Exp Med 103: 295–299
Skidgel RA, Schulz WW, Tam LT, Erdös EG (1987) Human renal
angiotensin converting enzyme and neutral endopeptidase. Kidney Int
31[suppl. 20]: S45–S48
233.
234.
235.
236.
237.
Skott O, Jensen BL (1993) Cellular and intrarenal control of renin
secretion. Clin Sci 84: 1–10
Soubrier F, Panthier JJ, Corvol P, Rougeon F (1983) Molecular cloning
and nucleotide sequence of a human renin cDNA. Nucleic Acid Res 11:
7181–7190
Soubrier F, Alhenc-Gelas F, Hubert C (1988) Two putative active centers
in human angiotensin I converting enzyme revealed by molecular cloning.
Proc Natl Acad Sci USA 85: 386–390
Stadler T, Veltmar A, Quadri F, Unger Th (1992) Angiotensin II evokes
noradrenaline release from the paraventricular nucleus in conscious rats.
Brain Res 569: 117–122
Stanislas-Leguern G, Mordeler Dambrine M, Dusser D, Huesca M,
Chretien J, Huchon GJ (1986) In vitro synthesis of angiotensin converting
enzyme by alveolar macrophages is increased in disseminated sarcoidosis.
Lung 164: 269–277
238.
239.
240.
241.
242.
243.
Stauss H, Unger Th (1991) Role of angiotensin II in thirst-induced
drinking. FASEB J 5(4): A658
Stauss H, Busch O, Unger Th (1992) Positiv inotroper Effekt von
zentralem Angiotensin II. Nieren und Hochdruckkrankheiten 11: 634–636
Steckelings U, Obermüller N, Bottari SP, Quadri F, Veltmar A, Unger Th
(1992) Brain angiotensin: receptors, actions and possible role in
hypertension. Pharmacol Toxicol 70 [suppl. II]: 23–27
Stoll M, Steckelings UM, Bottari SP, Unger Th (1993) Regulation of
endothelial cell growth: role of the angiotensin II AT2 receptor.
Circulation 88 [suppl. 4, part 2]: I-469
Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger Th
(1995) The angiotensin AT2-receptor mediates inhibition of cell
proliferation in coronary endothelial cells. J Clin Invest 95: 651–657
Stoll M, Meffert S, Stroth U, Unger Th (1995) Growth or antigrowth:
angiotensin and the endothelium. J Hypertens 13: 1529–1534
244.
245.
246.
247.
Sumners C, Tang W, Zelezna B, Raizada MK (1991) Angiotensin II
receptor subtypes are coupled with distinct signal-transduction
mechanisms in neurons and astrocytes from rat brain. Proc Ntal Acad Sci
USA 88: 7567–7571
Swanson GN, Hannesworth JN, Sardinia MF (1992) Discovery of a
distinct binding site for angiotensin (3–8) a putative angiotensin IV
receptor. Regul Pept 40: 409–419
Takeuchi K, Nakamura N, Cook NS, Pratt RE, Dzau VJ (1990)
Angiotensin II can regulate gene expression by the AP-1 binding sequence
via a protein kinase C-dependent pathway. Biochem Bophys Res
Commun172(3): 1189–1194
Tang J, James MNG, Hsu IN, Jenkins A, Blundell TL (1978) Structural
evidence for gene duplication in the evolution of acid proteases. Nature
271: 618–622
248.
249.
250.
251.
252.
253.
Tang SS, Loscalzo J, Dzau VJ (1989) Tissue plasminogen activator
activates renin-angiotensin in vitro. J Vasc Med Biol 1: 67–74
Taubman MB, Berk BC, Izumo S, Tsuda T, Alexander RW, Nadal-Ginard
B (1989) Angiotensin II induces c-fos mRNA in aortic smooth muscle. J
Biol Chem 264: 526–530
Tigerstedt R, Bergmann PG (1898) Niere und Kreislauf. Scand Arch
Physiol 8: 223–271
Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P,
Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD (1993) Angiotensin
II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:
205–251
Tobian L (1960) Interrelationship of electrolytes, juxtaglomerular cells
and hypertension. Physiol Rev 40: 280–312
Trolliet MR, Phillips MP (1992) The effect of chronic bilateral
nephrectomy on plasma and brain angiotensin. J Hypertens 10: 29–36
254.
255.
256.
257.
Tsutsumi K, Saveedra JM (1991) Characterization and development of
angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol
261: R209-R216
Tsutsumi K, Strömberg C, Viswanathan M, Saveedra JM (1991)
Angiotensin II receptor subtypes in fetal tissue of the rat: autoradiography,
guanine nucleotide sensivity, and association with phosphoinoside
hydrolysis. Endocrinology 129: 1075–1082
Tsutsumi K, Saveedra JM (1992) Heterogeneity of angiotensin II AT2
receptors in the rat brain. Mol Pharmacol 41: 290–297
Tsuzuki S, Ichiki T, Nakakubo H, Kitami Y, Guo DF, Shirai H, Inagami T
(1994) Molecular cloning and expression of the gene encoding human
angiotensin II type 2 receptor. Biochem Biophys Res Commun 20(3):
1449–1454
258.
259.
260.
261.
Unger Th, Rascher W, Schuster C (1981) Central blood pressure effects of
substance P and angiotensin II: Role of the sympathetic nervous system
and vasopressin. Eur J Pharmacol 71: 33–42
Unger Th, Schüll B, Hübner D (1981) Plasma converting enzyme activity
does not reflect effectiveness of oral treatment with captopril. Eur J
Pharmacol 72: 255–259
Unger Th, Yukimura T, Martin-Grez M, Lang RE, Rascher W, Ganten D
(1982) SA446, a new orally active converting enzyme inhibitor:
antihypertensive action and comparison with captopril in stroke-prone
spontaneusly hypertensive rats. Eur J Pharmacol 78: 411–420
Unger Th, Ganten D, Lang RE, Schölkens BA (1984) Is tissue converting
enzyme inhibition a determinant of the antihypertensive efficiacy of
converting enzyme inhibitors? Studies with two different compounds,
HOE498 and MK421, in spontaneously hypertensive rats. J Cardiovasc
Pharmacol 6: 872–880
262.
263.
264.
265.
266.
Unger Th, Becker H, Petty M (1985) Differenzial effects of central
angiotensin II and substance P on sympathetic nerve activity in conscious
rats. Circ Res 56: 563–575
Unger Th, Moursi M, Ganten D, Hermann K, Lang RE (1986)
Antihypertensive action of the converting enzyme inhibitor perindopril
(S9490–3) in spontaneously hypertensive rats: comparison with enalapril
(MK421) and ramipril (HOE498). J Cardiovasc Pharmacol 8: 276–285
Unger Th, Badoer E, Ganten D, Lang RE, Rettig R (1988) Brain
angiotensin: pathways and pharmacology. Circulation 77 [suppl. I]: I40I54
Unger Th, Gohlke P, Gruber MG (1990) Converting enzyme inhibitors. In:
Ganten D, Mulrow PJ eds. Handbook of experimental pharmacology, vol.
93. Berlin, Heidelberg: Springer-Verlag. 377–481
Unger Th, Gohlke P, Paul M, Rettig R (1991) Tissue renin angiotensin
system: fact or fiction? J Cardiovasc Pharmacol 19 [suppl. 2]: S20–S25
267.
268.
269.
270.
271.
Unger Th, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Höhle S,
Meffert S, Stoll M, Stroht U, Zhu YZ. (1996) Angiotensin receptors. J
Hypertens 14 (suppl. 5): S95–S103
Urata H, Healy B, Stewart RW, Bumpus FM, Husain A (1989)
Angiotensin II receptors in normal and failing human hearts. J Clin
Endocrinol Metab 69: 54–66
Urata H, Konoshita A, Misono KS, Bumpus FM, Husain A (1990)
Identification of a highly specific chymase as the major angiotensin II
forming enzyme in the human heart. J Biol Chem 265(36): 22348–22357
Velletri P, Bean BL (1982) The effects of captopril on rat aortic
angiotensin-converting enzyme. J Cardiovasc Pharmacol 4: 315–325
Veltmar A, Culman J, Qadri F, Rascher W, Unger Th (1992) Involvement
of adrenergic and angiotensinergic receptors in the paraventricular nucleus
in the angiotensin II-induced vasopressin release. J Pharmacol Exp Ther
263: 1253–1260
272.
273.
274.
275.
Viswanathan M, Tsutsumi K, Correa FMA, Saveedra JM (1991) Changes
in expression of angiotensin receptor subtypes in the rat aorta during
development. Biochem Biophys Res Commun 179: 1361–1367
Waldmann T, Qadri F, Rascher W, Culman J, Unger Th (1994)
Differenzial contribution of angiotensinergic and cholinergic receptors in
the paraventricular nucleus and supraoptic nucleus to osmotically induced
vasopressin release. J Hypertens 12 [suppl. 3]: 1069
Wang L, Eberhard M, Erne P (1995) Stimulation of cDNA and RNA
synthesis of cultured rabbit cardiac fibroblasts by angiotensin IV. Eur
Heart J 16 [suppl]: 451
Wei L, Alhenc-Gelas F, Corvol P, Clauser E (1992) The two homologous
domains of human angiotensin-I converting enzyme are both catalytically
active. J Biol Chem 266: 9002–9008
276.
277.
278.
279.
280.
Weintroub B, Klickstein LB, Dzau VJ, Watt KWK (1984) Granulocyteangiotensin system. Identification of angiotensinogen as substrate of
leukocyte cathepsin G. Biochemistry 23: 227–232
Welches WR, Santos RAS, Chappell MC, Brosnihan KB, Greene LJ,
Ferrario CM (1991) Evidence that prolyl endopeptidase participates in the
processing of brain angiotensin. J Hypertens 9: 631–638
Whitebread S, Mele M, Kamber B, deGasparo M (1989) Preliminary
biochemical characterization of two angiotensin II receptor subtypes.
Biochem Biophys Res Commun 163(1): 284–291
Wilkes BM (1987) Reduced glomerular angiotensin II receptor density in
diabetes mellitus in the rat: time course and mechanism. Endocrinology
120: 1291–1298
Wilkes BM, Pion I, Sollott S, Michaels S, Kiesel G (1988) Intrarenal
renin-angiotensin system modulates glomerular angiotensin receptors in
the rat. Am J Physiol 254: F345-F350
281.
282.
283.
284.
285.
Wilkes BM (1988) Increased angiotensin II receptor binding with age in
isolated rat glomeruli. Kidney Int 34: 241–247
Wilson SK, Lynch DR, Snyder SH (1987) Angiotensin converting enzyme
labelled with [3H]captopril. Tissue localizations and changes in different
models of hypertension in the rat. J Clin Invest 80: 841–851
Wolf G, Neilson EC (1990) Angiotensin II induces hypertrophy in
cultured murine proximal tubular cells. Am J Physiol 259: F768-F777
Ye MQ, Healy DP (1992) Characterization of an angiotensin type-1
receptor partial cDNA from rat kidney: evidence for a novel AT1b
receptor subtype. Biochem Biophys Res Commun 186: 1042–1049
Yoshida H, Kakuchi J, Guo DF (1992) Analysis of the evolution of
angiotensin II type 1 receptor gene in mammals (mouse, rat, bovine,
human). Biochem Biophys Res Commun 186: 1042–1049
286.
287.
Zhuo J, Song K, Harris PJ, Mendelsohn FAO (1992) In vitro
autoradiography reveals predominantly AT1 angiotensin II receptors in rat
kidney. Renal Physiol Biochem 15: 231–239
Zimmerman BG (1981) Adrenergic facilitation by angiotensin: does it
serve a physiological function. Clin Sci 60: 343–348
Literatur zu Kap. 14.4
1.
Agarwal MK (1994) Perspectives in receptor mediated mineralocorticoid
hormone action. Pharmacol Rev 46: 67–87
2.
Agarwal AK, Mune T, Monder C, White PC1995 Mutations in putative
glycosilation sites of rat 11β-hydroxysteroid dehydrogenase affect
enzymatic activity. Biochim Biophys Acta 1248: 70–74
3.
Agarwal MK, Mirshahi M (1999) General overview of mineralocorticoid
action. Pharmacology and Therapeutics 84: 273–326
4.
Alzamora R, Michea L, Marusic ET (2000) Role of 11ß-hydroxysteroid
dehydrogenase in nongenomic aldosterone efects in human arteries.
Hypertension 35: 1099–1104
5.
Arbuckle ND, Luisi B (1995) A recipe for specificity. Nature Struct Biol
2: 341–346
6.
Arriza JL, Weinberger C, Cerelli G, Glaser BL, Handelin DE, Honsman
DE, Evans RM (1987) Cloning of human mineralocorticoid receptor
7.
8.
9.
10.
11.
complementary DNA: Structural and functional kindship with the
glucocorticoid receptor. Science 237: 268–275
Bastl CP, Hayslett JP (1992) The cellular action of aldosterone in target
epithelia. Kidney Int 42: 250
Biglieri EG (1991) Spectrum of mineralocorticoid hypertension.
Hypertension 17: 251–256
Biglieri EG, Kater CE (1991) Mineralocorticoids in congenital adrenal
hyperplasia. J Steroid Biochem Molec Biol 40: 493–499
Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horlsberger J-D,
Rossier BC (1994) Amilorid-sensitive epithelial Na+ channel is made of
three homologous subunits. Nature 367: 463–467
Chang SS, Grunder S, Hanukoglu A, Rosler A, Mathew PM, Hanukoglu I,
Schild L, Lu Y, Shimkets RA, Nelson-Williams C, Rossier BC, Lifton RP
(1996) Mutations in sibunits of the epithelial sodium channel cause salt
12.
13.
14.
15.
vasting with hypokalemic acidosis pseudohypoaldosteronism typ 1. Nat
genetics 12: 248–253
Christ M, Sippel K, Eisen C, Wehling M (1994) Nonclassical receptors for
aldosterone in plasma membranes from pig kidneys. Mol Cell Endocrinol
99: R31–34
Couette B, Fagart J, Jalaguier S, Lombes M, Souque A, Rafestin-Oblin
ME (1996) The ligand induced conformational change of the
mineralocorticoid receptor occurs within its heterooligomeric structure.
Biochem J 315: 421–427
Couette B, Jalaguier S, Hella-Levy C, Lupo B, Fagart J, Auzou G,
Rafestin-Oblin ME (1998) Folding requirements of the ligand binding
domain of the human mineralocorticoid receptor. Mol Endocrinol 12: 855–
863
DeDuve C (1995) The beginning of life on earth. Am Sci 83: 428–437
16.
17.
18.
19.
20.
21.
Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ, Stallcup
MR (1998) Nuclear receptor binding sites of co-activators glucocorticoid
receptor interacting protein 1 (GRIP 1): Multiple motifs with different
binding specificity´s. Mol Endocrinol 12: 302–313
Edwards CRW, Stewart PM, Nairn IM, Grieve J, Shackleton CHL 1985
Cushing's disease of the kidney. J Endocrinol p1045
Evans RM (1988) The steroid and thyroid hormone receptor superfamily.
Science 240: 889–895
Fagart J, Wurtz J-M, Sonque A, Hellal-Levy C, Moras D, Rafestin-Oblin
M-E (1998) Antagonim in the human mineralocorticoid receptor. EMBO J
17: 3317–3325
Falkenstein E, Christ M, Feuring M, Wehling M (2000) Specific
nongenomic actions of aldosterone. Kidney Int 57: 1390–1394
Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L,
Pinto M, Huete A, Oestreicher E, Foradori A, Montero J (2000) Primary
22.
23.
24.
25.
26.
hyperaldosteronism in essential hypertensives: Prevalence, biochemical
profile, and molecular biology. J Clin Endocrinol Metab 85: 1863–1867
Farman N, Bocchi B (2000) Mineralocorticoid selectivity: Molecular and
cellular aspects. Kidney Intern 57: 1364–1369
Fejes-Tóth G, Pearce D, Náray-Fejes-Tóth A (1998) Subcellular
localization of mineralocorticoid receptors in living cells: Effects of
receptor agonists and antagonists. Proc Natl Acad Sci USA 95: 2973–2978
Ferrari P, Krozowski Z (2000) Role of the 11β-hydroxysteroid
dehydrogenase type 2 in blood pressure regulation. Kidney Inter 57: 1374–
1381
Ferrari P, Lovati E, Frey FJ 2000 The role of the 11β-hydroxysteroid
dehydrogenase type 2 in human hypertension. J Hypertension 18: 241–248
Galigniana MD, Vicent GP, Piwien-Pilipuk G, Burton G, Lantos CP
(2000) Mechanism of action of the potent sodium retaining steroid 11, 19oxidoprogesterone. Mol Pharamacol 58: 58–70
27.
28.
29.
30.
Garty H, Palmer LG (1997) Epithelial sodium channels: Function,
structure and regulation. Physiol Reviews 77: 359–396
Gekle M, Golenhofen N, Oberleithner H, Silbernagl S (1996) Rapid
actvation of Na+/H+ exchange by aldosterone in renal epithelial cells
require Ca2+ and stimulation of a plasma membrane proton conductance.
Proc Natl Acad Sci USA 93: 10500–10504
Geller DS, Rodriguez-Soriano J, Boado AV, Schifter S, Bayer M, Chang
SS, Lifton RP (1998) Mutations in the mineralocorticoid receptor gene
cause autosomal dominant pseudohypoaldosreronism type I. Nature Genet
19: 279–281
Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke
G, Tsai FTF, Sigler PB, Lifton RP (2000) Activating mineralocorticoid
receptor mutation in hypertension exacerbated by pregnancy. Science 289:
119–123
31.
32.
33.
34.
35.
Hong H, Kohli K, Garabedian MJ, Stallcup MR (1997) GRIP I, a
transcriptional co-activator for the AF2 transactivation domaine of steroid,
thyroid, retinoid and vitamin D receptors. Mol Cell Biol 17: 2735–2744
Jensen EV (1992) Remembrance: Gregory Pincus: a catalyst for early
receptor studies. Endocrinology 131: 1581–1582
Jorgensen PL, Andersen JP (1988) Strutural basis for E1-E2
conformational transitions in Na-K-pump and Ca-pump proteins. J Membr
biol 103: 95–120
Karlson P (1961) Biochemische Wirkungsweise der Hormone. Dtsch Med
Wochenschr 86: 668–674
Klein K, Henk W (1963) Klinisch-experimentelle Untersuchungen über
den Einfluss von Aldosteron auf Hämodynamik und Gerinnung. Z Kreisl
Forsch 52: 40–53
36.
37.
38.
39.
40.
Kolla V, Litwack G (2000) Trancriptional regulation of the human Na/K
ATPase via the human mineralocorticoid receptor. Mol Cell Biochem 204:
35–40
Krozowski ZS, Funder JW (1983) Renal mineralocorticoid receptors and
hippocampal corticosterone-binding species have identical intrinsic steroid
specifity. Proc Natl Acad Sci USA 80: 6056–6060
Lim-Tio SS, Keightley M-C, Fuller PJ (1997) Determinants of specificity
of transactivation by the mineralocortcoid or glucocorticoid receptor.
Endocrinology 138: 2537–2543
Lingrel JB, Kuntzweiler T (1994) Na+K+-ATPase. J Biol Chem 269:
19659–19662
Lingueglia E, Renard S, Waldmann R, Voilley N, Champigny G, Plass H,
Lazdunsk M, Barbry P (1994) Different homologous subunits of the
amilorid-sensitive Na+ channel are differently regulated by aldosterone. J
Biol Chem 269: 13736–13739
41.
42.
43.
44.
Liu W, Wang J, Sauter NK, Pearce D (1995) Steroid receptor
heterodimerisation demonstrated in vitro, and in vivo. Proc Natl Acad Sci
USA 92: 12480–12484
Lombes M, Kenouch S, Souque A, Farman N, Rafestin-Oblin ME (1994)
The mineralocorticoid receptor discriminates aldosterone from
glucocorticoids independently of the 11β-hydroxysteroid dehydrogenase.
Endocrinology 135: 834–840
Lombes M, Binart N, Delahaye F, Baulieu EE, Rafestin-Oblin ME (1994)
Differenzial intracellular localization of human mineralocorticoid receptor
on binding of agonists and antagonists. Biochem J 302: 191–197
Ludwig M, Bolkenius U, Wickert L, Bidlingmaier F (1998) Common
polymorphims in genes encoding the human mineralocorticoid receptor
and the human amiloride-sensitive sodium channel. J Steroid Biochem
Molec Biol 64: 227–230
45.
46.
47.
48.
Masilamani S, Kim GH, Mitchell C (1999) Aldosteron-mediated
regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney.
J Clin Invest 104: R19–25
McDonough AA, Magyar CE, Komatsu Y (1994) Expression of Na+K+ATPase α- and β-subunits along rat nephron: isoform specificity and
response to hypokalemia. Am J Physiol 267: C901–908
Minuth WW, Steckelings U, Gross P (1988) Appearance of specific
proteins in the apical plasma membrane of cultured renal collecting duct
principal cell epithelium after chronic administration of aldosterone and
arginine vasopressin. Differentiation 38: 194–198
Moura AM, Worcel M (1984) Direct action of alosterone on
transmembrane Na+ efflux from atrial smooth muscle. Hypertension 6:
425–430
49.
50.
51.
52.
Náray-Fejes-Tóth A, Fejes-Tóth G (2000) The sgk, an aldosterone-induced
gene in mineralocorticoid target cells, regulates the epithelial sodium
channel. Kidney Int 57: 1290–1294
New MI, Levine LS, Biglieri EG, Pareira J, Ulick S (1977) Evidence for
an unidentified steroid in a child with apparent mineralocorticoid
hypertension. J. Clin. Endocrinol. Metab. 44: 924–933
Obeyesekere VR, Ferrari P, Andrews RK, Wilson RC, New MI, Funder
JW, Krozowski ZS (1995) The R337C mutation generates a high Km 11βhydroxysteroid dehydrogenase type 2 enzyme in a family with apparent
mineralocorticoid excess. J Clin Endocronil Metab 80 3381–3383
O´Malley BW, Spelsberg TC, Scharder WT, Chytil F, Steggles AW
(1972) Mechanism of interaction of a hormon-receptor complex with the
genome of a eukaryotic target cell. Nature 235: 141–144
53.
54.
55.
56.
Patel PD, Sherman TG, Goldman DJ, Watson SJ (1989) Molecular cloning
of a mineralocorticoid (type I) receptor complementary DNA from rat
hippocampus. Mol Endocrinol 3: 1877–1885
Quinkler M, Johanssen S, Bumke-Vogt C, Oelkers W, Bähr V, Diederich
S (2001) Enzyme-mediated protection of the mineralocorticoid receptor
against progesterone in the human kidney. Mol Cell Endocrinol 171: 21–
24
Rafestin-Oblin ME, Couette B, Lombès M, Baulieu EE (1991)
Biochemical studies of the mineralocorticoid receptor: Oligometric
structure and anti-hormone action. In: Bonvalet JP, Farman N, Lombès M,
Rafestin-Oblin ME (Hrsg) Aldosterone: Fundamental aspects. Montrouge,
France: Coloque INSERM/John Libbey Eurotext Ltd. S55–64
Rogerson FM, Fuller PJ (2000) Mineralocorticoid action. Steroids 65: 61–
73
57.
58.
59.
60.
Rupprecht R, Arriza JL, Spengler D, Reul JMHM, Evans RM, Holsboer F,
Damm K (1993) Transactivation and synergistic properties of the
mineralocorticoid receptor: Relationship to tje glucocorticoid receptor.
Mol Endocrinol 7: 597–603
Shackleton CHL, Rodriquez J, Artega E, Lopez JM, Winter JSD (1985)
Congenital 11β-hydroxysteroid dehydrogenase deficiency associated with
juvenile hypertension: Corticosteroid metabolite profiles of four patients
and their families. Clin. Endocrinol. 22: 701–712
Shigaev A, Asher C, Latter H Garty H, Reuveny E (2000) Regulation of
sgk by aldosterone and its effects on the epithelial Na+ channel Am J
Physiol 278: F613–619
Shimkets RA, Warnock DG, Bosites CM, Nelson-Williams C, Hansson
JH, Schambelan M, Gill JR, Ulick S, Milora RV, Findling JW, Canessa
CM, Rossier BC, Lifton RP (1994) Liddle´s syndrome: heritable human
61.
62.
63.
64.
hypertension caused by mutations in the β-subunit of epithelial sodium
channel. Cell 79: 407–414
Shimkets RA, Lifton R, Canessa CM (1998) In vivo phosphorylation of
the epithelial sodium channel. Proc Natl Acad Sci USA 95: 3301
Spach C, Streeten DH (1964) Retardation of sodium exchange in dog
erythrocytes by physiological concentration of aldosterone, in vitro. J Clin
Invest 43: 217–227
Spindler B, Verrey F (1999) Aldosterone action: induction of p21 (ras) and
fra-2 and transcription-independent decrease in myc, jun and fos. Am J
Physiol 276: C1154–1162
Staub O, Yeger H, Plant PJ, Kim H, Ernst SA, Rotin D (1997) New
immunolocalization of the ubiquitin protein ligase nedd4 in tissues
expressing the epithelial Na channel (ENaC). Am J Physiol 272: C1871–
1880
65.
66.
67.
68.
Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie IFJ, Sheppard
MC, Whorwood CB (1996) Hypertension in the syndrome of apparent
mineralocorticoid excess due to mutation of the 11β-hydroxysteroid
dehydrogenase type 2 gene. Lancet 347: 88–91
Strautnieks SS, Thomson RJ, Gardiner RM, Chung E (1996) A novel
splice-site mutation in the γ-subunit of the epithelial sodium channel gene
in three pseudohypoaldosteronism type 1 families. Nat Genetics 13: 248–
250
Takeshita A, Cardona GR, Koibuchi N, Suen C-S, Chin WW (1997)
TRAM-I, a novel 160 kDa thyroid hormone receptor activator molecule,
exhibits distinct properties from steroid receptor coactivator-1. J Biol
Chem 272: 27629–27634
Trapp T, Holsboer F (1996) Heterodimerization between
mineralocorticoid and glucocorticoid receptors increases the functional
diversity of corticosteroid action. Trends Pharmacol Sci 17: 145–149
69.
70.
71.
72.
73.
Tsai MJ, O´Malley BW (1994) Molecular mechanisms of action of
sterid/thyroid receptor superfamily members. Ann Rev Biochem 63: 451–
486
Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W,
Rösler A, Bradlow HL, New MI (1979) A syndrome of apparent
mineralocorticoid excess associated with defects in the peripheral
metabolism of cortisol. J. Clin. Endocrinol. Metab. 49: 757–764
Verrey F (1999) Early aldosterone action: toward filling the gap between
transcription and transport. Am J Physiol 277: F319–326
Warnock DG (1998) Liddle syndrome: an autosomal dominant form of
human hypertension. Kidney Int 53: 18–24
Walker BR, Campbell JC, Williams BC, Edwards CRW (1992) Tissuespecific distribution of the NAD+-dependent isoform of 11βhydroxysteroid dehydrogenase. Endocrinol 131: 970–972
74.
75.
76.
77.
78.
Walker BR, Stewart PM, Shakleton C, Padfield PL, Edwars CRW (1993)
Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in
essential hypertansion. Clin Endocrinol 39: 221–227
Wehling M, Armanini D, Strasser T, Weber PC (1987) Effect of
aldosterone on the sodium and potassium concentrations in human
mononuclear leukocytes. Am J Physiol 252: E505–508
Wehling M, Käsmayr J, Theisen K (1991) Rapid effects of
mineralocorticoids on sodium-proton exchanger: Genomic or nongenomic
pathway? Am J Physiol 260: E719–726
Wehling M (1997) Specific, nongenomic actions of steroid hormones.
Annu Rev Physiol 59: 365–393
Wehling M, Spes Ch, Win N, Janson CP, Schmidt BMW, Theisen K,
Christ M (1998) Rapid cardiovascular action of aldosterone in man. J Clin
Endocrinol Metab 83: 3517–3522
79.
80.
81.
82.
White PC, Mune T, Agarwal AK (1997) 11 -hydroxysteroid
dehydrogenase and the syndrome of apparent mineralocorticoid excess.
Endocr Rev 18: 135–156
Whorwood CB, Stewart PM (1995) Transcriptional regulation of Na/KATPase by corticosteroids, glycyrrhetinic acid and second messenger
pathways in rat kidney epithelial cells. J Mol Endocrinol 15: 93–103
Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shakleton CH,
Hanauske-Abel HM, Wie JQ, Hertecau J, Morau A, Neiburger RE, Balfi
JW, Fattah A, Danemann D, Licholai T, New MI (1995) Several
homozygous mutations in the gene for 11β-hydroxysteroid dehydrogenase
type 2 in patients with apparent mineralocorticoid excess. J Clin
Endocrinol Metab 80: 3145–3150
Zange J, Müller K, Gerzer R, Sippel K, Wehling M (1996) Nongenomic
effects of aldosterone on phosphocreatine levels in human calf muscle
during recovery from exercise. J Clin Endocrinol Metab 81: 4296–4300
83.
Zennaro M-C, Farman N, Bonvalet J-P, Lombes M (1997) Tissue-specific
expression of α and β messenger ribonucleic acid isofprms of the human
mineralocorticoid receptor in normal and pathological states. J Clin
Endocrinol Metab 82: 1345–1352
Literatur zu Kap. 14.5
1.
James GD, Baker PT. Human population biology and blood pressure:
evolutionary and ecological considerations and interpretations of
population studies. In Hypertension: Pathophysiology, Diagnosis, and
Management. JH Laragh and BM Brenner (eds), New York, Raven Press,
1995; pp 115–126
2.
Ward R. Familial aggregation and genetic epidemiology of blood pressure.
In Hypertension: Pathophysiology, Diagnosis and Management. JH
Laragh and BM Brenner (eds), New York, Raven Press, 1995; pp 67–88
3.
Williams RR, Hunt SC, Hasstedt SJ. Current knowledge regarding the
genetics of human hypertension. J Hypertens 1989; 7(suppl): S8–13
4.
Neaton JD, Kuller L, Stamler J, Wentworth DN. Impact of systolic and
diastolic blood pressure on cardiovascular mortality. In Hypertension:
Pathophysiology, Diagnosis, and Management. JH Laragh and BM
Brenner (eds), New York, Raven Press, 1995; pp 127–144
5.
6.
7.
8.
9.
10.
Schiffrin EL, Intengan HD, Thibault G, Touyz RM. Clinical significance
of endothelin in cardiovascular disease. Curr Opin Cardiol 1997; 12: 354–
367
Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular
function in health and disease. J Hypertens 1998; 16: 1081–1098
Yanagisawa M, Kurihara H, Kimura S et al. A novel potent
vasoconstrictor peptide produced by vascular endothelial cells. Nature
1988; 332: 411–415
Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family:
three structurally and pharmacologically distinct isopeptides predicted by
three separate genes. Proc Natl Acad Sci U S A 1989; 86: 2863–2867
Levin ER. Endothelins. N Engl J Med 1995; 333: 356–363
Valdenaire O, Rohrbacher E, Mattei MG. Organization of the gene
encoding the human endothelin-converting enzyme (ECE-1). J Biol Chem
1995; 270: 29794–29798
11.
12.
13.
14.
Funke-Kaiser H, Orzechowski HD, Richter CM, Paul M. Human
endothelin-converting enzyme-1 beta mRNA expression is regulated by an
alternative promoter. J Cardiovasc Pharmacol 1998; 31(suppl.1): S7–9
Orzechowski HD, Richter CM, Funke-Kaiser H et al. Evidence of
alternative promoters directing isoform-specific expression of human
endothelin-converting enzyme-1 mRNA in cultured endothelial cells. J
Mol Med 1997; 75: 512–521
Hofstra RM, Valdenaire O, Arch E et al. A loss-of-function mutation in
the endothelin-converting enzyme 1 (ECE-1) associated with
Hirschsprung disease, cardiac defects, and autonomic dysfunction. Am J
Hum Genet 1999; 64: 304–308
Sakai S, Miyauchi T, Kobayashi M et al. Inhibition of myocardial
endothelin pathway improves long-term survival in heart failure. Nature
1996; 384: 353–355
15.
16.
17.
18.
19.
MacCumber MW, Ross CA, Glaser BM, Snyder SH. Endothelin:
visualization of mRNAs by in situ hybridization provides evidence for
local action. Proc Natl Acad Sci USA 1989; 86: 7285–7289
Ehrenreich H, Anderson RW, Fox CH et al. Endothelins, peptides with
potent vasoconstrictive properties, are produced by human macrophages. J
Exp Med 1990; 172: 1741–1748
Karet FE, Davenport AP. Localization of endothelin peptides in human
kidney. Kidney Int 1996; 49: 382–387
Lee ME, de la Monte SM, Ng SC, Bloch KD, Quertermous T. Expression
of the potent vasoconstrictor endothelin in human central nervous system.
J Clin Invest 1990; 86: 141–147
Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged
sword in health and disease. Annu Rev Pharmacol Toxicol 2001; 41: 851–
876
20.
21.
22.
23.
24.
Marsden PA, Dorfman DM, Collins T et al. Regulated expression of
endothelin 1 in glomerular capillary endothelial cells. Am J Physiol 1991;
261(1 Pt 2): F117–125
Zoja C, Orisio S, Perico N et al. Constitutive expression of endothelin
gene in cultured human mesangial cells and its modulation by
transforming growth factor-beta, thrombin, and a thromboxane A2
analogue. Lab Invest 1991; 64: 16–20
Cybulsky AV, Stewart DJ, Cybulsky MI. Glomerular epithelial cells
produce endothelin-1. J Am Soc Nephrol 1993; 3: 1398–1404
Kohan DE. Endothelin synthesis by rabbit renal tubule cells. Am J Physiol
1991; 261(2 Pt 2): F221–226
Emori T, Hirata Y, Imai T, Ohta K, Kanno K, et al. Cellular mechanism of
thrombin on endothelin-1 biosynthesis and release in bovine endothelial
cell. Biochem. Pharmacol 1992: 44: 2409–2411
25.
26.
27.
28.
29.
Kurihara H, Yoshizumi M, Sugiyama T et al. Transforming growth factorbeta stimulates the expression of endothelin mRNA by vascular
endothelial cells. Biochem Biophys Res Commun 1989; 159: 1435–1440
Yoshimoto S, Ishizaki Y, Sasaki T, Murota S. Effect of carbon dioxide and
oxygen on endothelin production by cultured porcine cerebral endothelial
cells. Stroke 1991; 22: 378–383
Boulanger C, Luscher TG. Release of endothelin from the porcine aorta.
Inhibition by endothelium derived nitric oxide. J Clin Invest 1990: 85:
587–590
Prins BA, Hu RM, Nazario B et al. Prostaglandin E2 and prostacyclin
inhibit the production and secretion of endothelin from cultured
endothelial cells. J Biol Chem 1994; 269: 11938–11944
Kohno M, Horio T, Yokokawa K, Kurihara N, Takeda T. C-type
natriuretic peptide inhibits thrombin and angiotensin II-stimulated
30.
31.
32.
33.
34.
endothelin release via cyclic guanosine 3', 5'-mono-phosphate.
Hypertension 1992; 19: 320–325
Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc
Pharmacol 1998; 32 (Suppl 3): S2–13
Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and
expression of a cDNA encoding an endothelin receptor. Nature 1990; 348:
730–732
Sakurai T, Yanagisawa M, Takuwa Y et al. Cloning of a cDNA encoding a
non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;
348: 732–735
Hosoda K, Nakao K, Hiroshi A et al. Cloning and expression of human
endothelin-1 receptor cDNA. FEBS Lett 1991; 287: 23–26
Frank HJ, Levin ER, Hu RM, Pedram A. Insulin stimulates endothelin
binding and action on cultured vascular smooth muscle cells.
Endocrinology 1993; 133: 1092–1097
35.
36.
37.
38.
39.
Redmond EM, Cahill PA, Hodges R, Zhang S, Sitzmann JV. Regulation of
endothelin receptors by nitric oxide in cultured rat vascular smooth muscle
cells. J Cell Physiol 1996; 166: 469–479
Levin ER. Endothelins. N Engl J Med 1995; 333: 356–363
Ogawa Y, Nakao K, Arai H et al. Molecular cloning of a non-isopeptideselective human endothelin receptor. Biochem Biophys Res Commun
1991; 178: 248–255
Smith PJ, Teichert-Kuliszewska K, Monge JC, Stewart DJ. Regulation of
endothelin-B receptor mRNA expression in human endothelial cells by
cytokines and growth factors. J Cardiovasc Pharmacol 1998; 31(Suppl. 1):
S158–160
Davenport AP, Maguire JJ. Is endothelin-induced vasoconstriction
mediated only by ETA receptors in humans? Trends Pharmacol Sci 1994;
15: 9–11
40.
41.
42.
43.
Seo B, Oemar BS, Siebenmann R, von Segersen L, Luscher TF. Both ETA
and ETB receptors mediate contraction to endothelin-1 in human blood
vessels. Circulation 1994; 89: 1203–1208
Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors
cause vasoconstriction of human resistance and capacitance vessels in
vivo. Circulation 1995; 92: 357–363
De Nucci G, Thomas R, D'Orleans-Juste P et al. Pressor effects of
circulating endothelin are limited by its removal in the pulmonary
circulation and by the release of prostacyclin and endothelium-derived
relaxing factor. Proc Natl Acad Sci U S A 1988; 85: 9797–9800
Fukuroda T, Fujikawa T, Ozaki S et al. Clearance of circulating
endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun
1994; 199: 1461–1465
44.
45.
46.
47.
48.
Kurihara Y, Kurihara H, Suzuki H et al. Elevated blood pressure and
craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;
368: 703–710
Kurihara Y, Kurihara H, Oda H et al. Aortic arch malformations and
ventricular septal defect in mice deficient in endothelin-1. J Clin Invest
1995; 96: 293–300
Clouthier DE, Hosoda K, Richardson JA et al. Cranial and cardiac neural
crest defects in endothelin-A receptor–deficient mice. Development 1998;
125: 813–824
Baynash AG, Hosoda K, Giaid A et al. Interaction of endothelin-3 with
endothelin-B receptor is essential for development of epidermal
melanocytes and enteric neurons. Cell. 79: 1994; 1277–1285
Hosoda K, Hammer RE, Richardson JA et al. Targeted and natural
(piebald-lethal) mutations of endothelin-B receptor gene produce
49.
50.
51.
52.
megacolon associated with spotted coat color in mice. Cell 1994; 79:
1267–1276
Brand M, Le Moullec JM, Corvol P, Gasc JM. Ontogeny of endothelins-1
and –3, their receptors, and endothelin converting enzyme-1 in the early
human embryo. J Clin Invest 1998; 101: 549–559
Yanagisawa H, Hammer RE, Richardson JA et al. Disruption of ECE-1
and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine
cardiac development. J Clin Invest 2000; 105: 1373–1382
Kisanuki Y, Ohuchi Y, Takahashi H et al. Endothelial cell-specific knockout of the endothelin-1 gene in mice. Presented at: Sixth International
Conference on Endothelins; October 10–13, 1999; Montreal, Canada.
Abstract
Rothermund L, Paul M. The role of endothelin in hypertension. Curr Opin
Nephrol Hypertens 1998; 7: 451–456
53.
54.
55.
56.
57.
Emori T, Hirata Y, Ohta K et al. Cellular mechanism of endothelin-1
release by angiotensin and vasopressin. Hypertension 1991; 18: 165–170
Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F.
Induction of endothelin-1 gene by angiotensin and vasopressin in
endothelial cells. Hypertension 1992; 19: 753–757
Sung CP, Arleth AJ, Storer BL, Ohlstein EH. Angiotensin type 1 receptors
mediate smooth muscle proliferation and endothelin biosynthesis in rat
vascular smooth muscle. J Pharmacol Exp Ther 1994; 271: 429–437
Maki S, Miyauchi T, Sakai S et al. Endothelin-1 expression in hearts of
transgenic hypertensive mice overexpressing angiotensin II. J Cardiovasc
Pharmacol 1998; 31(suppl.1): S412–416
Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Lüscher TF.
Angiotensin II increases tissue endothelin and induces vascular
hypertrophy – reversal by ETA-receptor antagonist. Circulation 1997; 96:
1593–1597
58.
59.
60.
61.
Barton M, Shaw S, d'Uscio LV, Moreau P, Lüscher TF. Angiotensin II
increases vascular and renal endothelin-1 and functional endothelinconverting enzyme activity in vivo – role of ETA receptors for endothelin
regulation. Biochem Biophys Res Commun 1997; 238: 861–865
Cozza EN, Gomez-Sanchez CE, Foecking MF, Chiou S. Endothelin
binding to cultured calf adrenal zona glomerulosa cells and stimulation of
aldosterone secretion. J Clin Invest 1989; 84: 1032–1035
Boarder MR, Marriott DB. Characterization of endothelin-1 stimulation of
catecholamine release from adrenal chromaffin cells. J Cardiovasc
Pharmacol 1989; 13(suppl.5): S223–224
Fukuda Y, Hirata Y, Yoshimi H et al. Endothelin is a potent secretagogue
for atrial natriuretic peptide in cultured rat atrial myocytes. Biochem
Biophys Res Commun 1988; 30; 155: 167–172
62.
63.
64.
65.
Stasch JP, Hirth-Dietrich C, Kazda S, Neuser D. Endothelin stimulates
release of atrial natriuretic peptides in vitro and in vivo. Life Sci 1989; 45:
869–875
Tabuchi Y, Nakamaru M, Rakugi H, Nagano M, Ogihara T. Endothelin
enhances adrenergic vasoconstriction in perfused rat mesenteric arteries.
Biochem Biophys Res Commun 1989; 159: 1304–1308
Yang ZH, Richard V, von Segesser L et al. Threshold concentrations of
endothelin-1 potentiate contractions to norepinephrine and serotonin in
human arteries. A new mechanism of vasospasm? Circulation 1990; 82:
188–195
Dohi Y, Hahn AW, Boulanger CM, Buhler FR, Lüscher TF. Endothelin
stimulated by angiotensin II augments contractility of spontaneously
hypertensive rat resistance arteries. Hypertension 1992; 19: 131–137
66.
67.
68.
69.
70.
Rubanyi GM, Polokoff MA. Endothelins: molecular biology,
biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol
Rev 1994; 46: 325–415
Ouchi Y, Kim S, Souza AC, Iijima S et al. Central effect of endothelin on
blood pressure in conscious rats. Am J Physiol 1989; 256: H1747–1751
Matsumura K, Abe I, Tsuchihashi T et al. Central effect of endothelin on
neurohormonal responses in conscious rabbits. Hypertension 1991; 17:
1192–1196
Nishimura M, Takahashi H, Matsusawa M et al. Chronic
intracerebroventricular infusions of endothelin elevate arterial pressure in
rats. J Hypertens 1991; 9: 71–76
Spyer KM, McQueen DS, Dashwood MR et al. Localization of
[125I]endothelin binding sites in the region of the carotid bifurcation and
brainstem of the cat: possible baro- and chemoreceptor involvement. J
Cardiovasc Pharmacol 1991; 17 Suppl 7: S385–389
71.
72.
73.
74.
75.
Komuro I, Kurihara H, Sugiyama T et al. Endothelin stimulates c-fos and
c-myc expression and proliferation of vascular smooth muscle cells. FEBS
Lett 1988; 238: 249–252
Alberts GF, Peifley KA, Johns A, Kleha JF, Winkles JA. Constitutive
endothelin-1 overexpression promotes smooth muscle cell proliferation via
an external autocrine loop. J Biol Chem 1994; 269: 10112–10118
Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen
for rat vascular smooth muscle cells. Atherosclerosis 1989; 78: 225–228
Badr KF, Murray JJ, Breyer MD et al. Mesangial cell, glomerular and
renal vascular responses to endothelin in the rat kidney. Elucidation of
signal transduction pathways. J Clin Invest 1989; 83: 336–342
Ito H, Hirata Y, Hiroe M et al. Endothelin-1 induces hypertrophy with
enhanced expression of muscle-specific genes in cultured neonatal rat
cardiomyocytes. Circ Res 1991; 69: 209–215
76.
77.
78.
79.
80.
81.
Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of
endothelin-1 gene in endothelium of resistance arteries in severe human
essential hypertension. J Hypertens 1997; 15: 57–63
Edwards RM, Trizna W, Ohlstein EH. Renal microvascular effects of
endothelin. Am J Physiol 1990; 259(2 Pt 2): F217–221
Miller WL, Redfield MM, Burnett JC Jr. Integrated cardiac, renal, and
endocrine actions of endothelin. J Clin Invest 1989; 83: 317–320
Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney
Dis 1997; 29: 2–26
Firth JD, Ratcliffe PJ, Raine AE, Ledingham JG. Endothelin: an important
factor in acute renal failure? Lancet 1988; 2: 1179–1182
Lopez-Farre A, Montanes I, Millas I, Lopez-Novoa JM. Effect of
endothelin on renal function in rats. Eur J Pharmacol 1989; 163: 187–189
82.
83.
84.
85.
86.
King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and
systemic vasoconstrictor peptide. Am J Physiol 1989; 256(6 Pt 2): F1051–
1058
Brooks DP, DePalma PD, Pullen M, Nambi P. Characterization of canine
renal endothelin receptor subtypes and their function. J Pharmacol Exp
Ther 1994; 268: 1091–1097
Maguire JJ, Kuc RE, O'Reilly G, Davenport AP. Vasoconstrictor
endothelin receptors characterized in human renal artery and vein in vitro.
Br J Pharmacol 1994; 113: 49–54
Pollock DM, Opgenorth TJ. Evidence for endothelin-induced renal
vasoconstriction independent of ETA receptor activation. Am J Physiol
1993; 264(1 Pt 2): R222–226
Kaasjager KA, Koomans HA, Rabelink TJ. Endothelin-1-induced
vasopressor responses in essential hypertension. Hypertension 1997; 30:
15–21
87.
88.
89.
90.
Kiowski W, Luscher TF, Linder L, Buhler FR. Endothelin-1-induced
vasoconstriction in humans. Reversal by calcium channel blockade but not
by nitrovasodilators or endothelium-derived relaxing factor. Circulation
1991; 83: 469–475
Filep JG, Foldes-Filep E, Rousseau A, Sirois P, Fournier A. Vascular
responses to endothelin-1 following inhibition of nitric oxide synthesis in
the conscious rats. Br J Pharmacol 1993; 110: 1213–1221
Berti F, Rossoni G, Della Bella D et al. Nitric oxide and prostacyclin
influence coronary vasomotor tone in perfused rabbit heart and modulate
endothelin-1 activity. J Cardiovas Pharmacol 1993; 22: 321–326
Bird JE, Waldron TL, Dorso CR, Asaad MM. Effects of endothelin
receptor antagonist BQ-123 on initial and delayed vascular responses
induced by ET-1 in concious, normotensive rats. J Cardiovasc Pharmacol
1993; 22: 69–73
91.
92.
93.
94.
95.
Wenzel RR, Fleisch M, Shaw S et al. Hemodynamic and coronary effects
of the endothelin antagonist bosentan in patients with coronary artery
disease. Circulation 1998; 98: 2235–2240
Haynes WG, Webb DJ. Contribution of endogenous generation of
endothelin-1 to basal vascular tone. Lancet 1994; 344: 852–854
Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO III, Panza JA. Role
of endothelin in the increased vascular tone of patients with essential
hypertension. Hypertension 1999; 33: 753–758
Donckier J, Stoleru L, Hayashida W et al. Role of endogenous endothelin1 in experimental renal hypertension in dogs. Circulation 1995; 92: 106–
113
Haynes WG, Ferro C, O'Kane K, Somerville D, Lomax C, Webb D.
Systemic endothelin receptor blockade decreases peripheral vascular
resistance and blood pressure in humans. Circulation 1996; 93: 1860–1870
96.
97.
98.
99.
100.
101.
Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of
an endothelin-receptor antagonist, bosentan, on blood pressure in patients
with essential hypertension. N Engl J Med 1998; 338: 784–790
Haynes WG, Hand MF, Johnstone HA, Padfield PL, Webb DJ. Direct and
sympathetically mediated venoconstriction in essential hypertension:
enhanced responses to endothelin-1. J Clin Invest 1994; 94: 1359–1364
Schiffrin EL, Thibault G. Plasma endothelin in human essential
hypertension. Am J Hypertens 1991; 4: 303–308
Shichiri M, Hirata Y, Ando K et al. Plasma endothelin levels in
hypertension and chronic renal failure. Hypertension 1990; 15: 493–496
Kohno M, Yasunari K, Murakawa K et al. Plasma immunoreactive
endothelin in essential hypertension. Am J Med 1990; 88: 614–618
Saito Y, Nakao K, Mukoyama M et al. Application of monoclonal
antibodies for endothelin to hypertensive research. Hypertension 1990; 15:
734–738
102.
103.
104.
105.
106.
Shichiri M, Hirata Y, Ando K et al. Plasma endothelin levels in
hypertension and chronic renal failure. Hypertension 1990; 15: 493–496
Lemne CE, Lundeberg T, Theodorsson E, De Faire U. Increased basal
concentrations of plasma endothelin in borderline hypertension. J
Hypertens 1994; 12: 1069–1074
Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin
level in patients with essential hypertension. N Engl J Med 1990; 322: 205
Battistini B, D'Orleans-Juste P, Sirois P. Biology of disease. Endothelins:
circulatory plasma levels and presence in other biologic fluids. Lab Invest
1993; 68: 600–628
Lüscher TF, Seo BG, Bühler FR. Potential role of endothelin in
hypertension. Controversy on endothelin in hypertension. Hypertension
1993; 21: 752–757
107.
108.
109.
110.
111.
Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma
endothelin-1 concentrations in individuals with essential hypertension.
Hypertension 1996; 28: 652–655
Letizia C, Cerci S, De Toma G et al. High plasma endothelin-1 levels in
hypertensive patients with low-renin essential hypertension. J Hum
Hypertens 1997; 11: 447–451
Parrinello G, Scaglione R, Pinto A et al. Central obesity and hypertension:
the role of plasma endothelin. Am J Hypertens 1996; 9: 1186–1191
Ferri C, Bellini C, Desideri G et al. Elevated plasma and urinary
endothelin-1 levels in human salt-sensitive hypertension. Clin Sci (Colch)
1997; 93: 35–41
Ferri C, Bellini C, Desideri G et al. Clustering of endothelial markers of
vascular damage in human salt-sensitive hypertension: influence of dietary
sodium load and depletion. Hypertension 1998; 32: 862–868
112.
113.
114.
115.
116.
Florijn KW, Derkx FH, Visser W et al. Elevated plasma levels of
endothelin in pre-eclampsia. J Hypertens Suppl 1991; 9: S166–167
Stockenhuber F, Gottsauner-Wolf M, Marosi L et al. Plasma levels of
endothelin in chronic renal failure and after renal transplantation: impact
on hypertension and cyclosporin A-associated nephrotoxicity. Clin Sci
1991; 82: 255–258
Shichiri M, Hirata Y, Ando K et al. Plasma endothelin levels in
hypertension and chronic renal failure. Hypertension 1990; 15: 493–496
Yoshimoto S, Ishizaki Y, Mori A, Sasaki T, Takakura K, Murota S. The
role of cerebral microvessel endothelium in regulation of cerebral blood
flow through production of endothelin-1. J Vasc Med Biol 1990; 2: 178
Wagner OF, Christ G, Wojta J et al. Polar secretion of endothelin-1 by
cultured endothelial cells. J Biol Chem 1992; 267: 16066–16068
117.
118.
119.
120.
121.
Howard PG, Plumpton C, Davenport AP. Anatomical localization and
pharmacological activity of mature endothelins and their precursors in
human vascular tissue. J Hypertens 1992; 10: 1379–1386
Battistini B, D'Orleans-Juste P, Sirois P. Endothelins: circulating plasma
levels and presence in other biologic fluids. Lab Invest 1993; 68: 600–628
Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin
antagonist on vascular remodeling in deoxycorticosterone acetate-salt
hypertensive rats. Evidence for a role of endothelin in vascular
hypertrophy. Hypertension 1994; 24: 183–188
d'Uscio LV, Barton M, Shaw S, Moreau P, Luscher TF. Structure and
function of small arteries in salt-induced hypertension: effects of chronic
endothelin-subtype-A-receptor blockade. Hypertension 1997; 30: 905–911
Day R, Lariviere R, Schiffrin EL. In situ hybridization shows increased
endothelin-1 mRNA levels in endothelial cells of blood vessels of
122.
123.
124.
deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens 1995;
8: 294–300
Karam H, Heudes D, Bruneval P et al. Endothelin antagonism in endorgan damage of spontaneously hypertensive rats: comparison with
angiotensin converting enzyme inhibition and calcium antagonism.
Hypertension 1996; 28: 379–385
Fujita K, Matsumura Y, Miyazaki Y, Takaoka M, Morimoto S. Effects of
the endothelin ETA-receptor antagonist FR139317 on develoment of
hypertension and cardiovascular hypertrophy in deoxycorticosterone
acetate-salt hypertensive rats. Jpn J Pharmacol 1996; 70: 313–319
Okada M, Kobayashi M, Maruyama H et al. Effects of a selective
endothelin A-receptor antagonist, BQ-123, in salt-loaded stroke-prone
spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1995; 22:
763–768
125.
126.
127.
128.
Karam H, Heudes D, Bruneval P et al. Endothelin antagonism in endorgan damage of spontaneously hypertensive rats. Comparison with
angiotensin-converting enzyme inhibition and calcium antagonism.
Hypertension 1996; 28: 379–385
Deng LY, Day R, Schiffrin EL. Localization of sites of enhanced
expression of endothelin-1 in the kidney of deoxycorticosterone acetatesalt hypertensive rats. J Am Soc Nephrol 1996; 7: 1158–1164
Ohuchi T, Kuwaki T, Ling G-Y et al. Elevation of blood pressure by
genetic and pharmacological disruption of the ETB receptor in mice. Am J
Physiol 1999; 45: R1071–R1077
Allcock GH, Venema RC, Pollock DM. ETA receptor blockade attenuates
the hypertension but not renal dysfunction in DOCA-salt rats. Am J
Physiol 1998; 44: R245–R252
129.
130.
131.
132.
133.
Obiefuna PCM, Ebeigbe AB, Sofola OA, Aloamaka CP. Altered responses
of aortic smooth muscle from Sprague-Dawley rats with salt-induced
hypertension. Clin Exp Pharmacol Physiol 1991; 18: 813–818
Ono A, Kuwaki T, Kumada M, Fujita T. Differential central modulation of
the baroreflex by salt loading in normotensive and spontaneously
hypertensive rats. Hypertension 1997; 29: 808–814
Park JB, Schiffrin EL. ETA receptor antagonist prevents blood pressure
elevation and vascular remodeling in aldosterone-infused rats.
Hypertension 2001; 37: 1444–1449
Ohuchi T, Kuwaki T, Ling G-Y et al. Elevation of blood pressure by
genetic and pharmacological disruption of the ETB receptor in mice. Am J
Physiol 1999; 45: R1071–R1077
Ohuchi T, Laghmani K, Yamada T et al. Salt-sensitive hypertension in
endothelin B receptor-deficient mice due to impaired renal salt excretion.
134.
135.
136.
137.
138.
Presented at: Sixth International Conference on Endothelins; October 10–
13, 1999; Montreal, Canada. Abstract
Elijovich F, Laffer CL, Amador E et al. Regulation of Plasma Endothelin
by Salt in Salt-Sensitive Hypertension. Circulation 2001; 103: 263–268
Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999; 353: 133–
138
Sütsch G, Kiowski W, Yan XW et al. Short-term oral endothelin-receptor
antagonist therapy in conventionally treated patients with symptomatic
severe chronic heart failure. Circulation 1998; 98: 2262–2268
Packer M, Caspi A, Charlon V et al. Multicenter, double-blind, placebocontrolled study of long-term endothelin blockade with bosentan in
chronic heart failure: results of the REACH-1 trial. Circulation 1998; 98:
I-3. Abstract
Verhaar MC, Strachan FE, Newby DE et al. Endothelin-A receptor
antagonist-mediated vasodilatation is attenuated by inhibition of nitric
oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;
97: 752–756
Literatur zu Kap. 14.6
1.
Bartosova D, Chvapil M, Korecky B et al. (1969) The growth of the
muscular and collagenous parts of the rat heart in various forms of
cardiomegaly. J Physiol 200: 185–195
2.
Brilla CG (1994) Cardiac structure-function relation in hypertension and
heart failure: role of the renin-angiotensin-aldosterone system. Current
Opinion in Cardiol 9 (Suppl 1): S2–S11
3.
Brilla CG (1994) Hochdruck und hypertensive Herzkrankheit:
Pathophysiologie, Klinik, Diagnostik und Therapie. De Gruyter, Berlin
4.
Brilla CG (1996) Renaissance der Therapie mit Aldosteronantagonisten
bei Herzinsuffizienz: eine Neubewertung von Spironolacton. Hoechst AG,
Frankfurt am Main
5.
Brilla CG, Weber KT (1992) Mineralocorticoid excess, dietary sodium
and myocardial fibrosis. J Lab Clin Med 120: 893–901
6.
7.
8.
9.
10.
Brilla CG, Kissling G, Jacob R (1987) Significance of right ventricular
filling for left ventricular enddiastolic pressure-volume relationship under
acute hypoxia in the dog. Basic Res Cardiol 82: 109–122
Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT (1990) Remodeling of
the rat right and left ventricle in experimental hypertension. Circ Res 67:
1355–1364
Brilla CG, Janicki JS, Weber KT (1991) Cardioreparative effects of
lisinopril in rats with genetic hypertension and left ventricular
hypertrophy. Circulation 83: 1771–1779
Brilla CG, Guarda E, Zhou G, Myers PR, Weber KT (1992) AngiotensinII-mediated aldosterone synthesis in aortic endothelial cells. Circulation 86
(Suppl I): I–90
Brilla CG, Matsubara L, Weber KT (1993) Anti-aldosterone treatment and
the prevention of myocardial fibrosis in primary and secondary
hyperaldosteronism. J Mol Cell Cardiol 25: 563–575
11.
12.
13.
14.
15.
Brilla CG, Zhou G, Matsubara L, Weber KT (1994) Collagen metabolism
in cultured adult rat cardiac fibroblasts: response to angiotensin II and
aldosterone. J Mol Cell Cardiol 26: 809–820
Brilla CG, Funck RC, Rupp H (2000) Lisinopril-mediated regression of
myocardial fibrosis in patients with hypertensive heart disease. Circulation
102: 1388–1393
Chapman D, Weber KT, Eghbali M (1990) Regulation of fibrillar collagen
types I and III and basement membrane type IV collagen gene expression
in pressure overloaded rat myocardium. Circ Res 67: 787–94
Harris P (1983) Evolution and the cardiac patient. Cardiovasc Res 17:
437–445
Holubarsch C, Holubarsch T, Jacob R, Medugorac I, Thiedemann K
(1983) Passive eleastic properties of myocardium in different models and
stages of hypertrophy: A study comparing mechanical, chemical and
morphometric parameters. Perspect Cardiovasc Res 7: 323–336
16.
17.
18.
19.
20.
Packer M (1988) Neurohormonal interactions and adaptations in
congestive heart failure. Circulation 77: 721–730
Pitt B (1995) "Escape" of aldosterone production in patients with left
ventricular dysfunction treated with an angiotensin converting enzyme
inhibitor: implications for therapy. Cardiovasc Drugs Ther 9: 145–149
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J,
Wittes J, for the Randomized Aldactone Evaluation Study Investigators
(1999) The effect of spironolactone on morbidity and mortality in patients
with severe heart failure. N Engl J Med 341: 709–717
Robert V, van Thiem N, Cheav SL, Mouas C, Swynghedauw B, Delcayre
C (1994) Increased cardiac types I and III collagen mRNAs in
aldosterone-salt hypertension. Hypertension 24: 30–36
Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic
JM, Swynghedauw B, Delcayre C (1998) Myocardial production of
21.
22.
23.
24.
aldosterone and corticosterone in the rat. Physiologic regulation. J Biol
Chem 273: 4883–4891
Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L (1990) Hormones
regulating cardiovascular function in patients with severe congestive heart
failure and their relation to mortality. Circulation 82: 1730–1736
Takeda R, Hatakeyama H, Takeda Y, Iki K, Miyamori I, Sheng WP,
Yamamoto H, Blair IA (1995) Aldosterone biosynthesis and action in
vascular cells. Steroids 60: 120–124
Weber KT, Brilla CG (1991) Pathologic hypertrophy and the cardiac
interstitium: Fibrosis and the renin-angiotensin-aldosterone system.
Circulation 83: 1849–1865
Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC,
Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV,
Mendelsohn FAO, Motz WH, Mulvany MJ, Strauer BE (1992)
25.
26.
27.
28.
Remodeling and Reparation of the cardiovascular system. J Am Coll
Cardiol 20: 3–16
Weber KT, Brilla CG, Cleland JGF, Cohn JN, Hansson L, Heagerty AM,
Laragh JH, Laurent S, Ollivier JP, Pauletto P, Pouleur H, Smits JFM, Tan
LB (1993) Cardioreparation and the concept of modulating cardiovascular
structure and function. Blood Pressure 2: 6–21
Wehling M, Käsmayr J, Theisen K (1991) Rapid effects of
mineralocorticoids on sodium-proton exchanger: genomic or nongenomic
pathway? Am J Physiol 260: E719-E726
Young M, Fullerton M, Dilley R, Funder J (1994) Mineralocorticoids,
Hypertension, and cardiac fibrosis. J Clin Invest 93: 2578–2583
Zannad F, Alla F, Dousset B, Perez A, Pitt B, on behalf of the RALES
Investigators. Limitation of excessive extracellular matrix turnover may
contribute to survival benefit of spironolactone therapy in patients with
congestive heart failure. Insights from the Randomized Aldactone
Evaluation Study (RALES) (2000) Circulation 102: 2700–2706
Literatur zu Kap. 14.7
1.
Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J,
Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L,
Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG.
Effect of blood pressure lowering and antihypertensive drug class on
progression of hypertensive kidney disease: results from the AASK trial.
JAMA 2002; 288: 2421–2431
2.
Cowley AW Jr, Roman RJ. The role of the kidney in hypertension. JAMA
1996; 275: 1581–1589
3.
Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle
acquired renal injury as a mechanism of salt-sensitive hypertension. N
Engl J Med 2002; 346: 913–923
4.
Selkurt EE. Effect of pulse pressure and mean arterial pressure
modification on renal hemodynamics and electrolyte and water excretion.
Circulation 1951; 4: 541–550
5.
6.
7.
8.
9.
Coleman TG, Guyton AC. Hypertension caused by salt loading in the
dog. Circ Res 1969; 25: 153–160
Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr,
Norman RA Jr. Arterial pressure regulation. Overriding dominance of the
kidneys in long-term regulation and in hypertension. Am J Med 1972; 52:
584–594
Guyton AC, Coleman TG, Cowley AW Jr, Liard JF, Norman RA Jr,
Manning RD Jr. Systems analysis of arterial pressure regulation and
hypertension. Ann Biomed Eng 1972; 1: 254–281
Luft FC, Rankin LI, Bloch R, Weyman AE, Willis LR, Murray RH, Grim
CE, Weinberger MH. Cardiovascular and humoral responses to extremes
of sodium intake in normal black and white men. Circulation 1979; 60:
697–706
Kimura G, Saito F, Kojima S, Yoshimi H, Abe H, Kawano Y, Yoshida K,
Ashida T, Kawamura M, Kuramochi M, et al. Renal function curve in
10.
11.
12.
13.
14.
patients with secondary forms of hypertension. Hypertension 1987; 10:
11–15
Kimura G, Imanishi M, Sanai T, Kawano Y, Kojima S, Yoshida K, Abe H,
Ashida T, Yoshimi H, Kawamura M, et al. Intrarenal hemodynamics in
patients with essential hypertension. Circ Res 1991; 69: 421–428
Roman RJ, Cowley AW Jr. Characterization of a new model for the study
of pressure-natriuresis in the rat. Am J Physiol 1985; 248: F190–F198
Roman RJ, Cowley AW Jr, Garcia-Estan J, Lombard JH. Pressure-diuresis
in volume-expanded rats. Cortical and medullary hemodynamics.
Hypertension 1988; 12: 168–176
Farrugia E, Lockhart JC, Larson TS. Relation between vasa recta blood
flow and renal interstitial hydrostatic pressure during pressure natriuresis.
Circ Res 1992; 71: 1153–1158
Mattson DL, Raff H, Roman RJ. Influence of angiotensin II on pressure
natriuresis and renal hemodynamics in volume-expanded rats. Am J
15.
16.
17.
18.
19.
20.
Physiol 1991; 260: R1200–R1209
DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev
1997; 77: 75–197
Brand PH, Coyne KB, Kostrzewski KA, Shier D, Metting PJ, Britton SL.
Pressure diuresis and autonomic function in conscious dogs. Am J Physiol
1991; 261: R802–R810
Ehmke H, Persson PB, Seyfarth M, Kirchheim HR. Neurogenic control of
pressure natriuresis in conscious dogs. Am J Physiol 1990; 259: F466–
F473
Dunn MJ, Hood VL. Prostaglandins and the kidney. Am J Physiol 1977;
233: 169–84
Roman RJ, Lianos E. Influence of prostaglandins on papillary blood flow
and pressure-natriuretic response. Hypertension 1990; 15: 29–35
Roman RJ, Kauker ML. Renal effect of prostaglandin synthetase
inhibition in rats: micropuncture studies. Am J Physiol 1978; 235: F111–
21.
22.
23.
24.
25.
F118
Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib
and rofecoxib on blood pressure and edema in patients >or =65 years of
age with systemic hypertension and osteoarthritis. Am J Cardiol 2002 Nov
1; 90: 959–963
Faubert PF, Chou SY, Porush JG. Regulation of papillary plasma flow by
angiotensin II. Kidney Int 1987; 32: 472–478
Chou SY, Porush JG, Faubert PF. Renal medullary circulation: hormonal
control. Kidney Int 1990; 37: 1–13
Hall JE. Control of sodium excretion by angiotensin II: intrarenal
mechanisms and blood pressure regulation. Am J Physiol 1986; 250:
R960–R972
Granger JP, Opgenorth TJ, Salazar J, Romero JC, Burnett JC Jr. Longterm hypotensive and renal effects of atrial natriuretic peptide.
Hypertension 1986; 8: II112–II116
26.
27.
28.
29.
30.
31.
Takezawa K, Cowley AW Jr, Skelton M, Roman RJ. Atriopeptin III alters
renal medullary hemodynamics and the pressure-diuresis response in rats.
Am J Physiol 1987; 252: F992–1002
Garcia-Estan J, Roman RJ. Role of renal interstitial hydrostatic pressure in
natriuretic response to ANP. Am J Physiol 1990; 258: R1333– R1339
Zatz R, de Nucci G. Effects of acute nitric oxide inhibition on rat
glomerular microcirculation. Am J Physiol 1991; 261: F360– F363
Baylis C, Harton P, Engels K. Endothelial derived relaxing factor controls
renal hemodynamics in the normal rat kidney. J Am Soc Nephrol 1990; 1:
875–881
Stein JH, Congbalay RC, Karsh DL, Osgood RW, Ferris TF. The effect of
bradykinin on proximal tubular sodium reabsorption in the dog: evidence
for functional nephron heterogeneity. J Clin Invest 1972; 51: 1709–1721
Roman RJ, Kaldunski ML, Scicli AG, Carretero OA. Influence of kinins
and angiotensin II on the regulation of papillary blood flow. Am J Physiol
32.
33.
34.
35.
1988; 255: F690– F698
Cowley AW Jr, Cushman WC, Quillen EW Jr, Skelton MM, Langford
HG. Vasopressin elevation in essential hypertension and increased
responsiveness to sodium intake. Hypertension 1981; 3: I93–100
Cowley AW Jr, Skelton MM, Velasquez MT. Sex differences in the
endocrine predictors of essential hypertension. Vasopressin versus renin.
Hypertension 1985; 7: I151–I160
Goldblatt H, Lynch J, Hanzal RF, Summerville WW. The production of
persistant elevation of systolic blood pressure by means of renal ischemia.
J Exp Med 1934; 59: 347–381
Bianchi G, Tenconi LT, Lucca R. Effect in the conscious dog of
constriction of the renal artery to a sole remaining kidney on
haemodynamics, sodium balance, body fluid volumes, plasma renin
concentration and pressor responsiveness to angiotensin. Clin Sci 1970;
38: 741–766
36.
37.
38.
39.
40.
Ledingham JM, Chohen RD. Changes in the extracellular fluid volume
and cardiac output during the development of experimental renal
hypertension. Can Med Assoc J 1964; 90: 292–294
Gross V, Lippoldt A, Bohlender J, Bader M, Hansson A, Luft FC. Cortical
and medullary hemodynamics in deoxycorticosterone acetate-salt
hypertensive mice. J Am Soc Nephrol 1998; 9: 346–354
Fenoy FJ, Kauker ML, Milicic I, Roman RJ. Normalization of pressurenatriuresis by nisoldipine in spontaneously hypertensive rats. Hypertension
1992; 19: 49–55
Kimura G, Deguchi F, Kojima S, Ashida T, Yoshimi H, Abe H, Kawano
Y, Yoshida K, Imanishi M, Kawamura M, et al. Antihypertensive drugs
and sodium restriction. Analysis of their interaction based on pressurenatriuresis relationship. Am J Hypertens 1988; 1: 372–379
Lu S, Roman RJ, Mattson DL, Cowley AW Jr. Renal medullary interstitial
infusion of diltiazem alters sodium and water excretion in rats. Am J
41.
42.
43.
44.
45.
Physiol 1992; 263: R1064– R1070
Gross V, Luft FC. Nisoldipine and pressure-natriuresis curves in
transgenic (mRen2)27 rats. J Hypertens 1996; 14: 529–535
Kline RL, Mercer PF. Effect of captopril and hydralazine on arterial
pressure-urinary output relationships in spontaneously hypertensive rats.
Hypertension 1987; 10: 590–594
Kline RL, Liu F. Modification of pressure natriuresis by long-term
losartan in spontaneously hypertensive rats. Hypertension 1994; 24: 467–
73
Dehmel B, Mervaala E, Lippoldt A, Gross V, Bohlender J, Ganten D, Luft
FC. Pressure-natriuresis and -diuresis in transgenic rats harboring both
human renin and human angiotensinogen genes. J Am Soc Nephrol 1998;
9: 2212–2222
Mervaala E, Dehmel B, Gross V, Lippoldt A, Bohlender J, Milia AF,
Ganten D, Luft FC. Angiotensin-converting enzyme inhibition and AT1
46.
47.
48.
49.
50.
receptor blockade modify the pressure-natriuresis relationship by additive
mechanisms in rats with human renin and angiotensinogen genes. J Am
Soc Nephrol 1999; 10: 1669–1680
Chen PY, Sanders PW. L-arginine abrogates salt-sensitive hypertension in
Dahl/Rapp rats. J Clin Invest 1991; 88: 1559–1567
Hall JE, Granger JP, Hester RL, Coleman TG, Smith MJ Jr, Cross RB.
Mechanisms of escape from sodium retention during angiotensin II
hypertension. Am J Physiol 1984; 246: F627–F634
Hall JE, Granger JP, Smith MJ Jr, Premen AJ. Role of renal
hemodynamics and arterial pressure in aldosterone "escape". Hypertension
1984; 6: I183–I192
Hall JE, Montani JP, Woods LL, Mizelle HL. Renal escape from
vasopressin: role of pressure diuresis. Am J Physiol 1986; 250: F907–
F916
Kawabe K, Watanabe TX, Shiono K, Sokabe H. Influence on blood
51.
52.
53.
54.
pressure of renal isografts between spontaneously hypertensive and
normotensive rats, utilizing the F1 hybrids. Jpn Heart J 1978; 19: 886–894
Rettig R, Stauss H, Folberth C, Ganten D, Waldherr B, Unger T.
Hypertension transmitted by kidneys from stroke-prone spontaneously
hypertensive rats. Am J Physiol 1989; 257: F197–203
Rettig R, Folberth C, Stauss H, Kopf D, Waldherr R, Unger T. Role of the
kidney in primary hypertension: a renal transplantation study in rats. Am J
Physiol 1990; 258: F606–F611
Rettig R, Folberth CG, Stauss H, Kopf D, Waldherr R, Baldauf G, Unger
T. Hypertension in rats induced by renal grafts from renovascular
hypertensive donors. Hypertension 1990; 15: 429–435
Bianchi G, Fox U, Di Francesco GF, Giovanetti AM, Pagetti D. Blood
pressure changes produced by kidney cross-transplantation between
spontaneously hypertensive rats and normotensive rats. Clin Sci Mol Med
1974; 47: 435–448
55.
56.
57.
58.
59.
Heller J, Schubert G, Havlickova J, Thurau K. The role of the kidney in
the development of hypertension: a transplantation study in the Prague
hypertensive rat. Pflugers Arch 1993; 425: 208–212
Dahl LK, Heine M, Thompson K. Genetic influence of the kidneys on
blood pressure. Evidence from chronic renal homografts in rats with
opposite predispositions to hypertension. Circ Res 1974; 40: 94–101
Churchill PC, Churchill MC, Bidani AK. Kidney cross transplants in Dahl
salt-sensitive and salt-resistant rats. Am J Physiol 1992; 262: H1809–
H1817
Churchill PC, Churchill MC, Bidani AK, Griffin KA, Picken M, Pravenec
M, Kren V, St Lezin E, Wang JM, Wang N, Kurtz TW. Genetic
susceptibility to hypertension-induced renal damage in the rat. Evidence
based on kidney-specific genome transfer. J Clin Invest 1997; 100: 1373–
1382
Guidi E, Cozzi MG, Minetti E, Bianchi G. Donor and recipient family
60.
61.
62.
63.
histories of hypertension influence renal impairment and blood pressure
during acute rejections. J Am Soc Nephrol 1998; 9: 2102–2107
Guidi E, Menghetti D, Milani S, Montagnino G, Palazzi P, Bianchi G.
Hypertension may be transplanted with the kidney in humans: a long-term
historical prospective follow-up of recipients grafted with kidneys coming
from donors with or without hypertension in their families. J Am Soc
Nephrol 1996; 7: 1131–1138
Strandgaard S, Hansen U. Hypertension in renal allograft recipients may
be conveyed by cadaveric kidneys from donors with subarachnoid
haemorrhage. Br Med J (Clin Res Ed) 1986; 292: 1041–1044
Curtis JJ, Luke RG, Dustan HP, Kashgarian M, Whelchel JD, Jones P,
Diethelm AG. Remission of essential hypertension after renal
transplantation. N Engl J Med 1983; 309: 1009–1015
Grim CE, Luft FC, Fineberg NS, Weinberger MH. Responses to volume
expansion and contraction in categorized hypertensive and normotensive
64.
65.
66.
67.
68.
man. Hypertension 1979; 1: 476–485
Luft FC, Miller JZ, Grim CE, Fineberg NS, Christian JC, Daugherty SA,
Weinberger MH. Salt sensitivity and resistance of blood pressure. Age and
race as factors in physiological responses. Hypertension 1991; 17: I102–
I108
Mai M, Geiger H, Hilgers KF, Veelken R, Mann JF, Dammrich J, Luft FC.
Early interstitial changes in hypertension-induced renal injury.
Hypertension 1993; 22: 754–765
Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J,
Schwartz SM. Renal injury from angiotensin II-mediated hypertension.
Hypertension 1992; 19: 464–474
Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, Johnson RJ.
Salt-sensitive hypertension develops after short-term exposure to
Angiotensin II. Hypertension 1999; 33: 1013–1019
Gross V, Luft FC. Adapting renal and cardiovascular physiology to the
genetically hypertensive mouse. Semin Nephrol 2002; 22: 172–179
Literatur zu Kap. 14.8
1.
Alexander RW, Griendling KK (1996) Signal transduction in vascular
smooth muscle. J Hypertens Suppl 14: S51–54
2.
Arii T, Ohyanagi M, Shibuya J, Iwasaki T (1999) Increased function of the
voltage-dependent calcium channels, without increase of Ca2+ release
from the sarcoplasmic reticulum in the arterioles of spontaneous
hypertensive rats. Am J Hypertens 12: 1236–1242
3.
Blankenship KA, Dawson CB, Aronoff GR, Dean WL (2000) Tyrosine
phosphorylation of human platelet plasma membrane Ca2+-ATPase in
hypertension. Hypertension 35: 103–107
4.
Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular
diseases: the role of oxidant stress. Circ Res 87: 840–844
5.
Dean WL, Pope JE, Brier ME, Aronoff GR (1994) Platelet calcium
transport in hypertension. Hypertension 23: 31–37
6.
7.
8.
9.
10.
Ek P, Toomik R, Eriksson S, Frithz G, Ronquist G, Engstrom L (1998)
Erythrocytic protein kinase C activity in primary hypertension. J Intern
Med 243: 299–305
Gulati S, Khullar M, Sharma BK, Ganguly NK (1996) Platelet calcium
pump activity in essential hypertensives and their first-degree relatives.
Mol Cell Biochem 156: 37–42
Hamlyn JM, Hamilton BP, Manunta P (1996) Endogenous ouabain,
sodium balance and blood pressure: a review and a hypothesis. Journal of
Hypertension 14: 151–167
Hoyer J, Köhler R, Haase W, Distler A (1996) Up-regulation of pressureactivated Ca2+-permeable cation channel in intact vascular endothelium of
hypertensive rats. Proc Natl Acad Sci U S A 93: 11253–11258
Intengan HD, Schiffrin EL (2000) Structure and mechanical properties of
resistance arteries in hypertension: role of adhesion molecules and
extracellular matrix determinants. Hypertension 36: 312–318
11.
12.
13.
14.
15.
Irani K (2000) Oxidant signaling in vascular cell growth, death, and
survival: a review of the roles of reactive oxygen species in smooth muscle
and endothelial cell mitogenic and apoptotic signaling. Circ Res 87: 179–
183
Kato N, Sugiyama T, Morita H, Kurihara H, Yamori Y, Yazaki Y (1998)
G protein beta3 subunit variant and essential hypertension in Japanese.
Hypertension 32: 935–938
Lompre AM (1999) Sarcoplasmic reticulum in vascular cells in
hypertension and during proliferation. Clin Exp Pharmacol Physiol 26:
553–557
Losse H, Wehmeyer H, Wessels F (1960) Der Wasser- und
Elektrolytgehalt von Erythrozyten bei essenzieller Hypertonie. Klinische
Wochenschrift 38: 393–395
Monteith GR, Kable EP, Kuo TH, Roufogalis BD (1997) Elevated plasma
membrane and sarcoplasmic reticulum Ca 2+ pump mRNA levels in
16.
17.
18.
19.
20.
cultured aortic smooth muscle cells from spontaneously hypertensive rats.
Biochem Biophys Res Commun 230: 344–346
Ohanian J, Heagerty AM (1992) The phosphoinositide signaling system
and hypertension. Curr Opin Nephrol Hypertens 1: 73–82
Ohya Y, Tsuchihashi T, Kagiyama S, Abe I, Fujishima M (1998) Single Ltype calcium channels in smooth muscle cells from resistance arteries of
spontaneously hypertensive rats. Hypertension 31: 1125–1129
Ohya Y, Adachi N, Nakamura Y, Setoguchi M, Abe I, Fujishima M
(1998) Stretch-activated channels in arterial smooth muscle of genetic
hypertensive rats. Hypertension 31: 254–258
Orlov SN, Adragna NC, Adarichev VA, Hamet P (1999) Genetic and
biochemical determinants of abnormal monovalent ion transport in
primary hypertension. Am J Physiol 276: C511–536
Savineau JP, Marthan R (1997) Modulation of the calcium sensitivity of
the smooth muscle contractile apparatus: molecular mechanisms,
21.
22.
23.
24.
25.
pharmacological and pathophysiological implications. Fundam Clin
Pharmacol 11: 289–299
Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T,
Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S (1997)
Calcium sensitization of smooth muscle mediated by a Rho-associated
protein kinase in hypertension. Nature 389: 990–994
Wechter WJ, Murray ED (1998) Has the elusive "natriuretic factor" been
discovered, and if so, is it a hormone? Exp Nephrol 6: 488–490
West IC, Rutherford PA, Thomas TH (1998) Sodium-lithium
countertransport: physiology and function. J Hypertens 16: 3–13
Yuan CM, Manunta P, Hamlyn JM et al. (1993) Long-term ouabain
administration produces hypertension in rats. Hypertension 22: 178–187
Zicha J, Kunes J, Devynck MA (1999) Abnormalities of membrane
function and lipid metabolism in hypertension: a review. Am J Hypertens
12: 315–331
Literatur zu Kap. 15
1.
2.
3.
4.
5.
Kannel WB, Gordon T, Schwartz MJ: Systolic vs. diastolisch blood
pressure an risk of coronary heart disease: The Framingham study. Am J
Cardiol 1971; 27: 335–346
Hansson L. et al. for the HOT Study Group: Effekts of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension:
principal results of the Hypertension Optimal Treatment (HOT)
randomised trial. Lancet 1998; 351: 1755–1762
UK Prospective Diabetes Study Group: Tight blood pressure control and
risk of macrovascular and microvascular complications in type 2 diabetes:
UKPDS 38.. BMJ 1998; 317 (7160): 703–13
Wilkinson IB, Webb Christison DJ, Cockcroft JR: Isolated systolic
hypertension: a radical rethink. BMJ 2000; 320: 1685
Rowe JW: Systolic Hypertension among the elderly. N Engl J Med 1983;
309: 1246–1247
6.
7.
8.
9.
10.
11.
Franklin S: Is there a preferred antihypertensive therapy for isolated
systolic hypertension and reduced arterial compliance. Current
Hypertension Reports 2000; 2: 253–259
Vaccarino V et al.: Puls pressure an the risk for myocardial infarction and
heart failure in the elderly. JAMA 2000; 36: 130–138
Athanase Benetos: Puls pressure and cardiovascular risk. J Hypertension
1999; 17 (suppl.5): 21–24
Staessen J et al.: Isolated systolic hypertension in the elderly. J Hypertens
1990; 8: 393–405
Vardan S, Mookherjee S: Perspectives on isolated systolic hypertension in
elderly patients. Ach Fam Med 2000; 9: 319–323
SHEP Cooperative Research Group. Prevention of stroke by
antihypertensive drug treatment in older persons with isolated
hypertension. Final results of the Systolic Hypertension in the Elderly
Program (SHEP). JAMA 1991; 265: 3255–3264
12.
13.
Thomas F, Bean K, Provost JC, Guize L, Benetos A: combined effects of
heart rate and pulse pressure on cardiovascular mortality according to age.
J Hypertension 2001; 19: 863–869
Staessen J et al.: Risks of untreated and treated isolated systolic
hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;
355: 865–872